

1026 3/18/97

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:sssptal644pnh
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Sep 29 The Philippines Inventory of Chemicals and Chemical
Substances (PICCS) has been added to CHEMLIST
NEWS 3 Oct 27 New Extraction Code PAX now available in Derwent
Files
NEWS 4 Oct 27 SET ABBREVIATIONS and SET PLURALS extended in
Derwent World Patents Index files
NEWS 5 Oct 27 Patent Assignee Code Dictionary now available
in Derwent Patent Files
NEWS 6 Oct 27 Plasdoc Key Serials Dictionary and Echoing added to
Derwent Subscriber Files WPIDS and WPIX
NEWS 7 Nov 29 Derwent announces further increase in updates for DWPI
NEWS 8 Dec 5 French Multi-Disciplinary Database PASCAL Now on STN
NEWS 9 Dec 5 Trademarks on STN - New DEMAS and EUMAS Files

NEWS EXPRESS FREE UPGRADE 5.0DP1 FOR STN EXPRESS 5.0 WITH DISCOVER!
(WINDOWS) NOW AVAILABLE
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:49:14 ON 10 DEC 2000

=> file medline embase biosis scisearch caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'MEDLINE' ENTERED AT 13:49:39 ON 10 DEC 2000

FILE 'EMBASE' ENTERED AT 13:49:39 ON 10 DEC 2000
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 13:49:39 ON 10 DEC 2000

COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'SCISEARCH' ENTERED AT 13:49:39 ON 10 DEC 2000

COPYRIGHT (C) 2000 Institute for Scientific Information (ISI) (R)

FILE 'CAPLUS' ENTERED AT 13:49:39 ON 10 DEC 2000

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

=> s fagales allergen

L1 2 FAGALES ALLERGEN

=> d l1 all 1-2

L1 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2000 ACS

AN 1999:614141 CAPLUS

DN 131:241995

TI Mutant recombinant allergens for use as allergy vaccines

IN Ipsen, Hans Henrik; Spangfort, Michael Dho; Larsen, Jorgen Nedergaard

PA Alk-Abello A/S, Den.

SO PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C12N015-29

ICS C12N015-12; C07K014-415; C07K014-435; A61K039-35; A61K039-36

CC 15-9 (Immunochemistry)

Section cross-reference(s): 3

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9947680	A1	19990923	WO 1999-DK136	19990316
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9927147	A1	19991011	AU 1999-27147	19990316
PRAI	DK 1998-364		19980316		
	WO 1999-DK136		19990316		

AB Novel recombinant allergens are disclosed. The allergens are non-naturally occurring mutants derived from naturally-occurring allergens. The overall .alpha.-carbon backbone tertiary structure is essentially preserved. Also disclosed are methods for prepg. such recombinant allergens as well as uses thereof. The invention is based on the idea that the mechanism of successful allergy vaccination is not an alteration of the ongoing Th2-type immune response, but rather a parallel initiation of a new Th1-type immune response involving tertiary epitope recognition by B-cells and antibody formation. Addnl., dominant IgE binding epitopes are proposed. These epitopes are supposed to be constituted by tertiary structure dependent coherent surface areas large

enough to accommodate antibody binding and conserved among isoallergens, variants, and/or homologous allergens from related species. Mutant forms of Bet v 1 and Ves v 5 allergens were produced. The Bet v 1 mutants displayed reduced IgE binding although the tertiary structure of the wild-type Bet v 1 allergen was retained. A "triple-patch mutant" of Bet

v 1 was able to induce proliferation in T cell lines from 3 different birch pollen allergic patients with stimulation indexes similar to recombinant and naturally occurring Bet v 1.

ST allergy vaccine allergen mutant B cell epitope IgE binding; Bet v 1 allergen recombinant mutant allergy vaccine; Ves v 5 allergen recombinant mutant allergy vaccine

IT Epitopes
 (B cell, mutation of; mutant recombinant allergens for use as allergy vaccines)

IT Allergens
 RL: BPN (Biosynthetic preparation); BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (Bet v I (Betula verrucosa, I); mutant recombinant allergens for use

as allergy vaccines)

IT Immunoglobulins
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (E, binding of, redn. of; mutant recombinant allergens for use as allergy vaccines)

IT Ant (Formicidae)
 (Formicoidae; mutant recombinant allergens for use as allergy vaccines)

IT Dicotyledon (Magnoliopsida)
 (Oleales; mutant recombinant allergens for use as allergy vaccines)

IT Monocotyledon (Liliopsida)
 (Poales; mutant recombinant allergens for use as allergy vaccines)

IT Allergens
 RL: BPN (Biosynthetic preparation); BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (Ves v 5 (Vespula vulgaris, V); mutant recombinant allergens for use

as allergy vaccines)

IT Animal
 Apidae
 Asterales
 Blattaria
 Cat (Felis catus)
 Dermatophagoides
 Dog (Canis familiaris)
Fagales
 Horse (Equus caballus)
 Hymenoptera
 Pinales
 Pollen
 Urticales
 Venoms
 Wasp
 (**allergens**; mutant recombinant allergens for use as allergy vaccines)

IT Vaccines

(allergy; mutant recombinant allergens for use as allergy vaccines)

IT Tertiary structure
(maintenance of; mutant recombinant allergens for use as allergy vaccines)

IT Allergy inhibitors
(mutant recombinant allergens for use as allergy vaccines)

IT Allergens
RL: BPN (Biosynthetic preparation); BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(mutant recombinant allergens for use as allergy vaccines)

IT Protein sequences
(of Bet v 1 and Ves v 5 mutants)

IT 244065-79-0P 244065-81-4P 244065-82-5P 244065-83-6P 244065-84-7P
244065-85-8P 244065-86-9P 244065-87-0P 244065-88-1P 244065-89-2P
244065-90-5P
RL: BPN (Biosynthetic preparation); BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(amino acid sequence; mutant recombinant allergens for use as allergy vaccines)

IT 244179-41-7, PN: WO9947680 FIG: 3 unclaimed DNA 244179-50-8, PN: WO9947680 FIG: 3 unclaimed DNA 244179-51-9, PN: WO9947680 FIG: 3 unclaimed DNA 244179-52-0, PN: WO9947680 FIG: 3 unclaimed DNA 244179-54-2, PN: WO9947680 FIG: 3 unclaimed DNA 244179-56-4, PN: WO9947680 FIG: 3 unclaimed DNA 244179-57-5, PN: WO9947680 FIG: 3 unclaimed DNA 244179-58-6, PN: WO9947680 FIG: 3 unclaimed DNA 244179-59-7, PN: WO9947680 FIG: 3 unclaimed DNA 244179-60-0, PN: WO9947680 FIG: 3 unclaimed DNA 244179-61-1, PN: WO9947680 FIG: 3 unclaimed DNA 244179-62-2, PN: WO9947680 FIG: 3 unclaimed DNA 244179-64-4, PN: WO9947680 FIG: 13 unclaimed DNA 244179-67-7, PN: WO9947680 FIG: 13 unclaimed DNA 244179-68-8, PN: WO9947680 FIG: 13 unclaimed DNA
RL: PRP (Properties)
(unclaimed nucleotide sequence; mutant recombinant allergens for use as allergy vaccines)

RE.CNT 6

RE

- (1) Ferreira, F; FASEB JOURNAL FOR EXPERIMENTAL BIOLOGY 1998, V12(2), P231 CAPLUS
- (2) Hoffman, D; JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 1993, V92(5), P707 MEDLINE
- (3) Smith, A; CLINICAL AND EXPERIMENTAL ALLERGY 1997, V27(5), P593 CAPLUS
- (4) Spangfort, M; INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 1997, V113(1-3), P243 CAPLUS
- (5) The Rockefeller University; WO 9733910 A 1997 CAPLUS
- (6) Wiedemann, P; JOURNAL OF BIOLOGICAL CHEMISTRY 1996, V271(47), P29915 CAPLUS

L1 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS

AN 1993:232158 CAPLUS

DN 118:232158

TI Four recombinant isoforms of Cor a I, the major allergen of hazel pollen, show different IgE-binding properties

AU Breiteneder, Heimo; Ferreira, Fatima; Hoffmann-Sommergruber, Karin; Ebner, Christof; Breitenbach, Michael; Rumpold, Helmut; Kraft, Dietrich;

Scheiner, Otto
CS Inst. Gen. Exp. Pathol., Univ. Vienna, Vienna, A-1090, Austria
SO Eur. J. Biochem. (1993), 212(2), 355-62
CODEN: EJBCAI; ISSN: 0014-2956
DT Journal
LA English
CC 15-9 (Immunochemistry)
Section cross-reference(s): 3, 11
AB Previous studies showed that pollens from trees of the order Fagales
(e.g. birch, alder, hazel, and hornbeam) all contain 1 major allergen. These
proteins are cross-reactive among these tree species, and .apprx.95% of
tree-pollen-allergic patients display IgE binding to these allergens.
Using the reported N-terminal amino acid sequence of the hazel pollen
allergen Cor a I, it was possible to amplify Cor-.alpha.-I cDNA by use of
PCR. Four clones with cDNA inserts were isolated. All 4 clones
contained an open reading frame of 477 nucleotides (159 amino acids) but differed
in length for their 3'-non-coding regions. Within the overlapping regions,
the nucleotide sequence of the 3'-non-coding regions of the 4 clones were
nearly identical. The open reading frames coded for different isoforms
of the major hazel pollen allergen, Cor a I. The clones were designated Cor
a I/5, 6, 11 and 16, resp. Comparison of the deduced amino acid
sequences of these Cor a I isoforms revealed identities of 96-99%. The sequence
identities between the Cor a I isoforms and Bet v I, the major birch
pollen allergen, were 71-73% (80.5-83% similarity). Comparing amino acid
sequences of Cor a I isoforms with the published sequences of Aln g I,
the major allergen from alder, and Car b I and isoforms, the major allergen
from hornbeam, 75.5-76.7% identity (83.6-85% similarity) and 83.6-89.9%
sequence identity (89.3-95% similarity), resp., was found. The 4 Cor a I
cDNAs were subcloned into plasmid pKK223-3 and expressed in Escherichia
coli as non-fusion proteins; their capacity to bind serum IgE from
tree-pollen-allergic patients was investigated. The 4 cloned isoforms
showed an apparent mol. mass of 17 kDa in SDS/PAGE, identical to the
natural, pollen-derived Cor a I. IgE antibodies from
tree-pollen-allergic patients reacted with all 4 recombinant isoforms. However, marked
differences were noted in the IgE-binding patterns of the distinct
isoforms. Furthermore, Cor a I/11 was the only isoform recognized by the
anti-(Ber v I) monoclonal antibody, BIP 1. These results demonstrate
that Cor a I isoforms display different antigenic and allergenic properties,
very likely due to few but significant changes in their amino acid
sequences. These findings have implications for the development of
reagents for diagnosis and immunotherapy for type I allergies.
ST hazel pollen allergen isoform; Corylus major allergen I sequence
IT **Fagales**
(allergens of pollen of, human IgE to, hazel major allergen I
isoforms reactivity for)
IT Protein sequences
(for allergen I isoforms of hazel)
IT Immunoglobulins
RL: BIOL (Biological study)
(E, to allergen I of hazel, of humans, isoform reactivity of)

IT Deoxyribonucleic acid sequences
 (complementary, for allergen I isoforms of hazel)
 IT Allergy
 (immediate hypersensitivity, IgE to tree pollen of humans with, hazel
 major allergen I isoform reactivity of)
 IT 143066-17-5, Allergen Cor a I (hazel isoform 1) 143066-18-6, Allergen
 Cor a I (hazel isoform 2) 143066-19-7, Allergen Cor a I (hazel isoform
 3) 143066-20-0, Allergen Cor a I (hazel isoform 4)
 RL: PRP (Properties)
 (amino acid sequence of)

=> s birch allergen

L2 155 BIRCH ALLERGEN

=> s l2 and beta v1

L3 0 L2 AND BETA V1

=> s l2 and epitope

L4 27 L2 AND EPITOPE

=> dup remove l4

PROCESSING COMPLETED FOR L4

L5 26 DUP REMOVE L4 (1 DUPLICATE REMOVED)

=> d l5 all 1-26

L5 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 2000:469064 CAPLUS

DN 133:191900

TI Rapid production of the major birch pollen allergen Bet v 1 in Nicotiana
 benthamiana plants and its immunological in vitro and in vivo
 characterization

AU Krebitz, Monika; Wiedermann, Ursula; Essl, Dagmar; Steinkellner, Herta;
 Wagner, Birgit; Turpen, Thomas H.; Ebner, Christof; Scheiner, Otto;
 Breiteneder, Heimo

CS Department of Pathophysiology, University of Vienna, Vienna, 1090,
 Austria

SO FASEB J. (2000), 14(10), 1279-1288

CODEN: FAJOEC; ISSN: 0892-6638

PB Federation of American Societies for Experimental Biology

DT Journal

LA English

CC 15-9 (Immunochemistry)

AB Type I allergies are immunol. disorders that afflict a quarter of the
 world's population. Improved diagnosis of allergic diseases and the
 formulation of new therapeutic approaches are based on the use of
 recombinant allergens. The authors describe here for the first time the
 application of a rapid plant-based expression system for a plant-derived
 allergen and its immunol. characterization. The authors expressed the
 authors' model allergen Bet v 1, the major birch pollen allergen, in the
 tobacco-related species Nicotiana benthamiana using a tobacco mosaic

virus

vector. Two weeks post-inoculation, plants infected with recombinant viral RNA contg. the Bet v 1 coding sequence accumulated the allergen to levels of 200 .mu.g/g leaf material. Total non-purified protein exts. from plants were used for immunol. characterizations. IgE immunoblots and ELISA inhibition assays showed comparable IgE binding properties for tobacco recombinant (r) Bet v 1 and natural (n) Bet v 1, suggesting that the B cell **epitopes** were preserved when the allergen was expressed in *N. benthamiana* plants. Using a murine model of type I allergy, mice immunized with crude leaf exts. contg. Bet v 1 with purified rBet v 1 produced in *E. coli* or with birch pollen ext. generated comparable allergen-specific IgE and IgG1 antibody responses and pos. type I skin test reactions. These results demonstrate that non-purified Bet v 1 overexpressed in *N. benthamiana* has the same immunogenicity as purified Bet v 1 produced in *E. coli* or nBet v 1. The authors therefore conclude that this plant expression system offers a viable alternative to fermn.-based prodn. of allergens in bacteria or yeasts. In addn., there may be a broad utility of this system for the development of new and low-cost vaccination strategies against allergy.

ST Bet v1 allergen tobacco; **birch allergen** *Nicotiana*
IT Allergens
RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation) (Bet v I (Betula verrucosa, I); prepn. and immunol. characterization of birch pollen allergen from tobacco)

IT Immunoglobulins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (E; to tobacco-derived birch pollen allergen)

IT Immunoglobulins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (G1; to tobacco-derived birch pollen allergen)

IT Tobacco mosaic virus
(as vector for expression of birch pollen allergen in *Nicotiana benthamiana*)

IT Tobacco (*Nicotiana benthamiana*)
(prepn. and immunol. characterization of birch pollen allergen from)

IT Birch (*Betula*)
(prepn. and immunol. characterization of birch pollen allergen from tobacco)

IT Virus vectors
(tobacco mosaic virus as vector for expression of birch pollen allergen in *Nicotiana benthamiana*)

RE.CNT 41
RE
(1) Arakawa, T; Transgenic Res 1997, V6, P403 CAPLUS
(2) Bauer, L; Clin Exp Immunol 1997, V107, P536 CAPLUS
(3) Breiteneder, H; EMBO J 1989, V8, P1935
(4) Casper, S; Gene 1996, V173, P69 CAPLUS
(5) Ebner, C; Eur J Immunol 1993, V23, P1523 CAPLUS
(6) Ebner, C; J Immunol 1993, V150, P1047 CAPLUS
(7) Ebner, C; J Immunol 1995, V154, P1932 CAPLUS
(8) Ferreira, F; J Biol Chem 1993, V268, P19574 CAPLUS
(9) Ferreira, F; J Exp Med 1996, V183, P599 CAPLUS
(10) Gajhede, M; Natl Struct Biol 1996, V3, P1040 CAPLUS

- (11) Godnic-Cvar, J; J Allergy Clin Immunol 1997, V99, P354 CAPLUS
- (12) Hakkart, G; Clin Exp Allergy 1998, V28, P45
- (13) Haq, T; Science 1995, V268, P714 CAPLUS
- (14) Hoffmann-Sommergruber, K; Gene 1997, V197, P91 CAPLUS
- (15) Hoffmann-Sommergruber, K; Protein Exp Purif 1997, V9, P33 CAPLUS
- (16) Hoyne, G; Int Immunol 1996, V7, P335
- (17) Huecas, S; Eur J Biochem 1999, V261, P539 CAPLUS
- (18) Ipsen, H; J Allergy Clin Immunol 1983, V72, P150 CAPLUS
- (19) Jarolim, E; Allergy 1989, V44, P385 MEDLINE
- (20) Jarolim, E; Int Arch Allergy Appl Immunol 1989, V90, P54 CAPLUS
- (21) Koo, M; Proc Natl Acad Sci USA 1999, V96, P7774 CAPLUS
- (22) Kraft, D; Allergy 1998, V53, P62 MEDLINE
- (23) Kraft, D; Int Arch Allergy Immunol 1999, V118, P171 CAPLUS
- (24) Kumagai, M; Proc Natl Acad Sci USA 1993, V90, P427 CAPLUS
- (25) Mason, H; Proc Natl Acad Sci USA 1992, V89, P11745 CAPLUS
- (26) Mason, H; Proc Natl Acad Sci USA 1996, V93, P5335 CAPLUS
- (27) McCormick, A; Proc Natl Acad Sci USA 1999, V96, P703 CAPLUS
- (28) Seymour, B; J Exp Med 1998, V187, P721 CAPLUS
- (29) Smith, P; J Allergy Clin Immunol 1996, V98, P331 CAPLUS
- (30) Sowka, S; Eur J Biochem 1998, V255, P213 CAPLUS
- (31) Sowka, S; J Biol Chem 1998, V273, P28091 CAPLUS
- (32) Swoboda, I; J Biol Chem 1995, V270, P2607 CAPLUS
- (33) Turpen, T; Bio/Technology 1995, V13, P53 CAPLUS
- (34) Vailes, L; J Allergy Clin Immunol 1998, V101, P274 CAPLUS
- (35) Valenta, R; Curr Opin Immunol 1995, V7, P751 CAPLUS
- (36) Vrtala, S; J Clin Invest 1997, V99, P1673 CAPLUS
- (37) Wen, J; Mol Phyl Evol 1997, V8, P317 CAPLUS
- (38) Wiedermann, U; Clin Exp Immunol 1998, V111, P144 CAPLUS
- (39) Wiedermann, U; Int Immunol 1999, V11, P1131 CAPLUS
- (40) Wiedermann, U; J Allergy Clin Immunol 1999, V103, P1202 CAPLUS
- (41) Yasue, M; Cell Immunol 1997, V181, P30 CAPLUS

L5 ANSWER 2 OF 26 MEDLINE

AN 1999384123 MEDLINE

DN 99384123

TI Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation.

AU van Neerven R J; Wikborg T; Lund G; Jacobsen B; Brinch-Nielsen A; Arnved J; Ipsen H

CS ALK-Abello, Horsholm, Denmark; and Lung and Allergy Clinic, Copenhagen, Denmark.. joost-vanneerven@tanox.nl

SO JOURNAL OF IMMUNOLOGY, (1999 Sep 1) 163 (5) 2944-52.

Journal code: IFB. ISSN: 0022-1767.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals

EM 199911

EW 19991104

AB Allergen-specific CD4+ T lymphocytes are activated at extremely low allergen concentrations in vivo as a result of serum-facilitated allergen presentation (S-FAP). It is not clear at present if specific allergy vaccination (SAV) has an effect on this mechanism. Here we show that **birch allergen**-specific serum-IgE facilitates the presentation of Bet v 1, the major birch pollen allergen, to Bet v 1-specific CD4+ T lymphocytes by a factor of >100. This process is CD23 mediated, could be detected in sera from the majority of birch-allergic

patients, and was clearly dose dependent. S-FAP of Bet v 1 was inhibited in patients undergoing long-term birch SAV, but not by sera from patients undergoing grass SAV, indicating that birch-specific Abs are involved. This resulted in decreased proliferation and IL-4, IL-5, IL-10, and IFN-gamma production of Bet v 1-specific T cells. The inhibition was already noted after 3-9 mo of SAV and could not be solely explained by increased serum levels of birch-specific IgG4. When IgG- and IgA/IgM-containing fractions of long-term SAV sera were used to inhibit S-FAP, only IgG-containing fractions were shown to inhibit S-FAP. These results indicate that blocking IgG Abs induced by SAV inhibits the occurrence of S-FAP at very low allergen concentrations, resulting in significantly higher allergen threshold levels to obtain T cell proliferation and cytokine production and thus allergen-induced

late-phase

responses.

CT Check Tags: Human

*Allergens: IM, immunology

Allergens: ME, metabolism

Antibodies, Anti-Idiotypic: PH, physiology

*Antibodies, Blocking: BI, biosynthesis

*Antibodies, Blocking: PH, physiology

*Antigen Presentation: IM, immunology

Antigens, CD19: IM, immunology

Body Temperature

Cells, Cultured

*CD4-Positive T-Lymphocytes: IM, immunology

CD4-Positive T-Lymphocytes: ME, metabolism

Desensitization, Immunologic

Epitopes, T-Lymphocyte: IM, immunology

*IgE: BL, blood

IgE: IM, immunology

IgE: PH, physiology

IgG: BL, blood

IgG: IM, immunology

Immune Sera: PH, physiology

*Lymphocyte Transformation: IM, immunology

*Plant Proteins: IM, immunology

Plant Proteins: ME, metabolism

Receptors, IgE: IM, immunology

Trees: IM, immunology

RN 126161-14-6 (BetvI protein); 37341-29-0 (IgE)

CN 0 (anti-IgE); 0 (anti-IgG); 0 (Allergens); 0 (Antibodies,

Anti-Idiotypic);

0 (Antibodies, Blocking); 0 (Antigens, CD19); 0 (**Epitopes,**

T-Lymphocyte); 0 (IgG); 0 (Immune Sera); 0 (Plant Proteins); 0

(Receptors,

IgE)

L5 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1999:273002 CAPLUS

DN 131:115196

TI Identification of a highly promiscuous and an HLA allele-specific T-cell **epitope** in the birch major allergen Bet v 1: HLA restriction, **epitope** mapping and TCR sequence comparisons

AU Friedl-Hajek, R.; Spangfort, M. D.; Schou, C.; Breiteneder, H.; Yssel, H.;

Van Neerven, R. J. Joost

CS Department of General and Experimental Pathology, Vienna, Austria

SO Clin. Exp. Allergy (1999), 29(4), 478-487
 CODEN: CLEAEN; ISSN: 0954-7894
 PB Blackwell Science Ltd.
 DT Journal
 LA English
 CC 15-9 (Immunochemistry)
 Section cross-reference(s): 3

AB Background: allergen-specific CD4+ T cells play an important regulatory role in atopic allergy. Objective: to investigate the human leukocyte antigen (HLA) restriction and T-cell receptor (TCR) usage of allergen-specific T-cell clones (TCCs) that react with defined **epitopes** of Bet v 1, the major birch pollen allergen. Methods: five Bet v 1-specific TCCs derived from two birch pollen-allergic individuals and specific for Bet v 1, were **epitope**-mapped with overlapping synthetic peptides. In addn., HLA-restriction and TCR CDR3 sequences were detd. Results: three TCCs reacted with a Bet v 1 peptide contg. amino acid residues 21-33 (BP21), the other two TCCs reacted with a minimal peptide comprising residues 37-45 (BP37). Studies using neutralizing anti-HLA-monoclonal antibodies and HLA-typed APCs showed that the BP37-specific TCCs were restricted by a HLA-DQA1*0301/DQB1*0603 heterodimer. In contrast, BP21 was recognized in a highly promiscuous manner. TCCs recognizing this sequence were restricted by HLA-DPB1*0201, a HLA-DQA1*0201/DQB1*0201 heterodimer, or HLA-DRB3*0101. Reverse transcription-polymerase chain reaction with primers for all known TCRAV and TCRBV gene segments, followed by CDR3 region sequencing, revealed the usage of five different TCRAV and four different TCRBV gene segments by the TCCs, as well as diversity in the joining region. All BP21-specific TCCs contained a neg. charged residue in their CDR3.alpha. regions, the CDR3.beta. regions showed a high concn. of polar and OH-group bearing residues. BP37-specific TCCs shared the amino acid combination LY in the middle of their CDR3.alpha. regions, the CDR3.beta. regions showed high concn. of OH-group bearing or charged residues. Conclusions: this study shows the existence of a highly promiscuous T-cell **epitope** in Bet v 1. The presence of addnl. T-cell **epitopes** in Bet v 1 may, however, hamper the clin. applicability of the **epitope**. Likewise, the diversity in TCR usage by T cells recognizing the **epitope** does not support the development of TCR-directed immunotherapy for birch pollen allergy.

ST **birch allergen** Betv1 T cell **epitope** HLA restriction; TCR receptor cDNA sequence **birch allergen** human

IT Allergens
 RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence);
 PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
 (Bet v 1 (Betula verrucosa, 1); highly promiscuous and human HLA allele-specific T-cell **epitope** in birch major allergen Bet v 1 and HLA restriction, **epitope** mapping and TCR sequence comparisons)

IT Histocompatibility antigens
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BIOL (Biological study); PROC (Process)
 (HLA-DP; highly promiscuous and human HLA allele-specific T-cell **epitope** in birch major allergen Bet v 1 and HLA restriction, **epitope** mapping and TCR sequence comparisons)

IT Gene, animal

RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
 (HLA-DPB1; highly promiscuous and human HLA allele-specific T-cell **epitope** in birch major allergen Bet v 1 and HLA restriction, **epitope** mapping and TCR sequence comparisons)

IT Histocompatibility antigens
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BIOL (Biological study); PROC (Process)
 (HLA-DQ; highly promiscuous and human HLA allele-specific T-cell **epitope** in birch major allergen Bet v 1 and HLA restriction, **epitope** mapping and TCR sequence comparisons)

IT Gene, animal
 RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
 (HLA-DQA1; highly promiscuous and human HLA allele-specific T-cell **epitope** in birch major allergen Bet v 1 and HLA restriction, **epitope** mapping and TCR sequence comparisons)

IT Gene, animal
 RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
 (HLA-DQB1; highly promiscuous and human HLA allele-specific T-cell **epitope** in birch major allergen Bet v 1 and HLA restriction, **epitope** mapping and TCR sequence comparisons)

IT Histocompatibility antigens
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BIOL (Biological study); PROC (Process)
 (HLA-DR; highly promiscuous and human HLA allele-specific T-cell **epitope** in birch major allergen Bet v 1 and HLA restriction, **epitope** mapping and TCR sequence comparisons)

IT Gene, animal
 RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
 (HLA-DRB3; highly promiscuous and human HLA allele-specific T-cell **epitope** in birch major allergen Bet v 1 and HLA restriction, **epitope** mapping and TCR sequence comparisons)

IT Allergy
 (atopy; highly promiscuous and human HLA allele-specific T-cell **epitope** in birch major allergen Bet v 1 and HLA restriction, **epitope** mapping and TCR sequence comparisons)

IT Peptides, biological studies
 RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
 (**epitope**; highly promiscuous and human HLA allele-specific T-cell **epitope** in birch major allergen Bet v 1 and HLA restriction, **epitope** mapping and TCR sequence comparisons)

IT Alleles
 Birch (Betula pendula)
 CD4-positive T cell
 MHC restriction
 Protein sequences
 cDNA sequences
 (highly promiscuous and human HLA allele-specific T-cell **epitope** in birch major allergen Bet v 1 and HLA restriction, **epitope** mapping and TCR sequence comparisons)

IT Gene, animal
 TCR .alpha..beta. (receptor)
 RL: BOC (Biological occurrence); PRP (Properties); BIOL (Biological

study); OCCU (Occurrence)
 (highly promiscuous and human HLA allele-specific T-cell
epitope in birch major allergen Bet v 1 and HLA restriction,
epitope mapping and TCR sequence comparisons)

IT **Epitopes**
 (mapping; highly promiscuous and human HLA allele-specific T-cell
epitope in birch major allergen Bet v 1 and HLA restriction,
epitope mapping and TCR sequence comparisons)

IT **Epitopes**
 (peptide; highly promiscuous and human HLA allele-specific T-cell
epitope in birch major allergen Bet v 1 and HLA restriction,
epitope mapping and TCR sequence comparisons)

IT 232260-84-3 232260-85-4
 RL: ADV (Adverse effect, including toxicity); BOC (Biological
 occurrence);
 PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
 (**epitope**; highly promiscuous and human HLA allele-specific
 T-cell **epitope** in birch major allergen Bet v 1 and HLA
 restriction, **epitope** mapping and TCR sequence comparisons)

IT 199415-74-2, GenBank Y15198 199415-75-3, GenBank Y15199 199415-76-4,
 GenBank Y15200 199415-77-5, GenBank Y15201 199415-78-6, GenBank
 Y15202
 199415-79-7, GenBank Y15203 199415-80-0, GenBank Y15204 199415-81-1,
 GenBank Y15205 199415-82-2, GenBank Y15206 199415-83-3, GenBank
 Y15207
 RL: PRP (Properties)
 (nucleotide sequence; highly promiscuous and human HLA allele-specific
 T-cell **epitope** in birch major allergen Bet v 1 and HLA
 restriction, **epitope** mapping and TCR sequence comparisons)

RE.CNT 35
 RE
 (1) Bowness, P; Eur J Immunol 1993, V23, P1417 CAPLUS
 (2) Breiteneder, H; EMBO J 1989, V8, P1935 CAPLUS
 (3) Breiteneder, H; Eur J Biochem 1993, V552, P1
 (4) Breiteneder, H; Immunogenetics 1995, V42, P53 CAPLUS
 (5) Breiteneder, H; J Allergy Clin Immunol 1992, V90, P909 MEDLINE
 (6) Brown, L; Int Immunol 1991, V3, P1307 MEDLINE
 (7) Davies, M; Nature 1988, V334, P395
 (8) de Campos-Lima, P; J Exp Med 1997, V186, P83 CAPLUS
 (9) Del Simonian, H; J Exp Med 1993, V177, P1623
 (10) Durham, S; J Immunol 1992, V148, P2390 CAPLUS
 (11) Gajhede, M; Nature Struct Biol 1996, V3, P1040 CAPLUS
 (12) Garcia, K; An ab T cell receptor structure at 2.5 A and its orientation
 in
 the TCR-MHC complex Sci 1996, V274, P209 CAPLUS
 (13) Hamid, Q; J Allergy Clin Immunol 1997, V99, P254 CAPLUS
 (14) Henwood, J; Eur J Immunol 1993, V23, P1256 CAPLUS
 (15) Ipsen, H; Clin Exp Allergy 1992, V22, P391 MEDLINE
 (16) Ipsen, H; J Allergy Clin Immunol 1983, V72, P150 CAPLUS
 (17) Jutel, M; J Immunol 1995, V154, P4187 CAPLUS
 (18) Kay, A; J Exp Med 1991, V173, P775 CAPLUS
 (19) Lannes-Viera, J; Eur J Immunol 1995, V25, P611 MEDLINE
 (20) Larsen, J; Mol Immunol 1992, V29, P703 CAPLUS
 (21) Marsh, S; Tissue Antigens 1995, V45, P258
 (22) May, E; Int Immunol 1996, V8, P1815 CAPLUS
 (23) Meinel, E; J Clin Invest 1993, V92, P2633 CAPLUS
 (24) Moss, P; Immunogenetics 1995, V42, P10 CAPLUS
 (25) Moss, P; Proc Natl Acad Sci USA 1991, V88, P8987 CAPLUS

- (26) Robinson, D; N Engl J Med 1992, V326, P298 MEDLINE
- (27) Rock, E; J Exp Med 1994, V79, P323
- (28) Secrist, H; J Exp Med 1993, V178, P2123 CAPLUS
- (29) Struyk, L; Hum Immunol 1995, V44, P220 CAPLUS
- (30) van Neerven, R; Clin exp Allergy 1998, V28, P423 CAPLUS
- (31) van Neerven, R; Immunol Today 1996, V17, P526 MEDLINE
- (32) van de Vijver, C; Eur J Immunol 1995, V25, P958
- (33) Varney, V; J Clin Invest 1993, V92, P644 MEDLINE
- (34) Wedderburn, L; Proc Natl Acad Sci USA 1993, V90, P8214 CAPLUS
- (35) Wierenga, E; J Immunol 1990, V144, P4651 MEDLINE

L5 ANSWER 4 OF 26 BIOSIS COPYRIGHT 2000 BIOSIS

AN 2000:9412 BIOSIS

DN PREV200000009412

TI Pollen-related food allergy: Cloning and immunological analysis of isoforms and mutants of Mal d 1, the major apple allergen, and Bet v 1, the major birch pollen allergen.

AU Son, D. Y.; Scheurer, S.; Hoffmann, A.; Haustein, D.; Vieths, S. (1)

CS (1) Department of Allergology, Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, D-63225, Langen Germany

SO European Journal of Nutrition, (Aug., 1999) Vol. 38, No. 4, pp. 201-215. ISSN: 1436-6207.

DT Article

LA English

SL English

AB Background: Mal d 1, the major apple allergen, cross-reacts with IgE specific for the major birch pollen allergen, Bet v 1, and is responsible for birch pollen related food allergy to apple. Isoforms of Bet v 1 showing minor sequence variations display different binding capacity for specific IgE antibodies from allergic patients. Moreover, strain-dependent

variation of allergenicity has been reported for apples. Objective: To investigate the occurrence of strain-dependent isoforms of Mal d 1 which may differ in their allergenic potential, to obtain data on structures essential for binding of Mal d 1 to the antibody, and to gain insights into the structures responsible for its IgE cross-reactivity to Bet v 1. Methods: The cDNA of Mal d 1 from various apple strains was amplified by

a PCR strategy based on conserved regions of known Mal d 1-sequences, and sequenced. Two major isoforms of Mal d 1 were expressed as recombinant proteins and purified, as were different variants of the major birch pollen allergen, Bet v 1. Together with already existing recombinant

birch pollen and apple allergens, these were subjected to allergenicity testing by IgE-immunoblotting, enzyme allerge sorbent test and dose related mediator release. "Hot-spots" for IgE-reactivity were identified by site-directed mutagenesis. Results: Twelve Mal d 1-clones were sequenced from 7 apple varieties and compared to 3 known Mal d 1 sequences. The clones were clustered into two groups, each showing a high degree of sequence identity to one of the known sequences and specific differences to the third sequence. No strain-specific sequences were identified. In contrast, apple strains with reported differences in allergenicity showed different expression levels of the major allergen. Immunologic testing of recombinant allergens revealed high IgE binding capacity of 2 major isoforms, named GD26 and GS29, with a slightly higher IgE binding capacity

of GD26. Moreover, the allergenicity was similar to another rMal d 1 reported in the literature, representing the isoform divergent from our

clones. Mutational analysis of our Mal d 1 allergens identified serine in position 111 as essential for IgE binding. Allergenicity was almost depleted by changing this residue into a proline. Moreover, the corresponding serine residue, present in position 112 of Bet v 1, was in a similar manner crucial for the allergenicity of the birch pollen allergen.

Conclusion: We conclude that divergent allergenicity of apple strains mainly depends on different expression levels of the major allergen. Introduction of a proline residue in position 111 of Mal d 1 and in position 112 of Bet v 1 led to a drastic reduction of allergenicity of both the pollen and the food allergen, obviously also removing the cross-reactive **epitope**. Mutants with reduced IgE-reactivity but maintained T-cell reactivity may represent new candidates for a safer specific immunotherapy with reduced side-effects.

CC Nutrition - General Studies, Nutritional Status and Methods *13202
 Genetics and Cytogenetics - General *03502
 Biochemical Studies - General *10060
 Immunology and Immunochemistry - General; Methods *34502
 Allergy *35500
 Food Technology - General; Methods *13502
 Biophysics - General Biophysical Studies *10502

BC Hominidae 86215

IT Major Concepts
 Molecular Genetics (Biochemistry and Molecular Biophysics); Immune System (Chemical Coordination and Homeostasis); Foods; Nutrition

IT Chemicals & Biochemicals
 Bet v 1: allergen, expression, immunological analysis, major **birch allergen**, molecular cloning; IgE [immunoglobulin E]; Mal d 1: allergen, expression, immunological analysis, major apple allergen, molecular cloning

IT Methods & Equipment
 PCR [polymerase chain reaction]: DNA amplification method; SDS-PAGE [SDS-polyacrylamide gel electrophoresis]: separation method; Western blotting: detection method; site-directed mutagenesis: genetic method

IT Miscellaneous Descriptors
 food allergy: pollen-related

ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia;
 Muridae:
 Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
 BALB/c mouse (Muridae); human (Hominidae): patient

ORGN Organism Superterms
 Animals; Chordates; Humans; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Primates; Rodents; Vertebrates

L5 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2000 ACS
 AN 1997:232478 CAPLUS
 DN 126:304872
 TI Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T-cell **epitope**-containing fragments. Candidates for a novel form of specific immunotherapy

AU Vrtala, Susanne; Hirtenlehner, Kora; Vangelista, Luca; Pastore, Annalisa; Eichler, Hans-Georg; Sperr, Wolfgang R.; Valent, Peter; Ebner, Christof; Kraft, Dietrich; Valenta, Rudolf

CS Department of Immunopathology, Institute of General and Experimental Pathology, AKH, University of Vienna, Vienna, A-1090, Austria

SO J. Clin. Invest. (1997), 99(7), 1673-1681
 CODEN: JCINAO; ISSN: 0021-9738
 PB Rockefeller University Press
 DT Journal
 LA English
 CC 15-9 (Immunochemistry)
 AB A novel approach to reduce the anaphylactic activity of allergens is suggested. The strategy makes use of the presence of conformational IgE **epitopes** on one of the most common allergens. The three dimensional structure of the major birch pollen allergen, Bet v 1, was disrupted by expressing two parts of the Bet v 1 cDNA representing amino acids 1-74 and 75-160 in Escherichia coli. In contrast to the complete recombinant Bet v 1, the fragments showed almost no allergenicity and exhibited random coil conformation as analyzed by CD. Both nonanaphylactic fragments induced proliferation of human Bet v 1-specific T cell clones, indicating that they harbored all dominant T cell **epitopes** and therefore may be considered as a basis for the development of a safe and specific T cell immunotherapy.
 ST **birch allergen** conversion anaphylactic activity;
 immunotherapy allergen conversion T cell **epitope**
 IT Allergens
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); RCT (Reactant); BIOL (Biological study); PREP (Preparation)
 (Bet v I (Betula verrucosa, I), recombinant fragments; conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell **epitope**-contg. fragments and specific immunotherapy)
 IT Anaphylaxis
 Conformation
 Immunotherapy
 (conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell **epitope**-contg. fragments and specific immunotherapy)
 IT T cell (lymphocyte)
 (**epitope**; conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell **epitope**-contg. fragments and specific immunotherapy)
 IT IgE
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (**epitopes**; conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell **epitope**-contg. fragments and specific immunotherapy)
 L5 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2000 ACS
 AN 1997:568660 CAPLUS
 DN 127:247038
 TI Crossreactivity and T-cell **epitope** specificity of Bet v 1-specific T cells suggest the involvement of multiple isoallergens in sensitization to birch pollen
 AU Sparholt, S. H.; Larsen, J. N.; Ipsen, H.; Schou, C.; Van Neerven, R. J. J.
 CS ALK ABELLO, Horsholm, DK-2970, Den.
 SO Clin. Exp. Allergy (1997), 27(8), 932-941
 CODEN: CLEAEN; ISSN: 0954-7894
 PB Blackwell
 DT Journal
 LA English
 CC 15-9 (Immunochemistry)

AB Allergen-specific T lymphocytes play an important role in the pathophysiol. of atopic disease. Detailed studies of their **epitope**-specificity and crossreactivity are required for the development of novel approaches for specific immunotherapy. The aim of the study was to characterize the fine specificity of Bet v 1-specific T cells from allergic donors. Polyclonal T-cell lines (TCL) and T-cell clones (TCC), specific for Bet v 1, the major birch (*Betula verrucosa*) pollen allergen, were isolated from the peripheral blood of three birch-allergic patients. Their **epitope**-specificity was studied using overlapping synthetic peptides, and crossreactivity with other tree pollen allergens of the Fagales order was evaluated. In addn., the Bet v 1-specific TCC were studied for their phenotype and cytokine prodn. All isolated Bet v 1-specific TCC (19/21 CD4+, 2/21 CD8+) reacted with affinity purified Bet v 1, but showed different reactivities with recombinant Bet v 1 (rBet v 1), and with group 1 allergens from other Fagales species. **Epitope** mapping of rBet v 1-reactive TCC with synthetic peptides of Bet v 1 showed the presence of four T-cell **epitopes**. Polyclonal T-cell lines reacted with 13 different peptides, and displayed even broader crossreactivity with group 1 pollen allergens from other Fagales members. This study demonstrates that apart from T-cell **epitopes** of rBet v 1, many other crossreactive or Bet v 1 isoallergen-specific **epitopes** exist. This indicates that isoallergenic variation plays an important role in the induction of Bet v 1-specific and crossreactive T-cell responsiveness to allergens.

ST T cell **epitope** specificity Betula allergen; **birch allergen** T cell crossreactivity

IT Allergens
 RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
 (Bet v I (*Betula verrucosa*, I); crossreactivity and **epitope** specificity of human T-cells to birch pollen allergen)

IT Alder (*Alnus glutinosa*)
 Birch (*Betula pendula*)
 CD4-positive T cell
 CD8-positive T cell
 Carpinus betulus
Epitopes
 Fagales
 Hazel (*Corylus avellana*)
 Oak (*Quercus alba*)
 (crossreactivity and **epitope** specificity of human T-cells to birch pollen allergen)

IT Peptides, biological studies
 RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
 (crossreactivity and **epitope** specificity of human T-cells to birch pollen allergen)

IT 195702-59-1 195702-63-7 195702-66-0 195702-68-2 195702-71-7
 195702-74-0 195702-76-2 195702-78-4 195702-80-8 195702-82-0
 195702-85-3 195702-87-5 195702-89-7
 RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
 (crossreactivity and **epitope** specificity of human T-cells to birch pollen allergen)

L5 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2000 ACS
 AN 1997:228346 CAPLUS
 DN 126:249944

TI Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell **epitope** from the major birch pollen allergen Bet v 1
 AU Bauer, L.; Bohle, B.; Jahn-Schmid, B.; Wiedermann, U.; Daser, A.; Renz, H.; Kraft, D.; Ebner, C.
 CS Institute of General and Experimental Pathology, AKH, University of Vienna, Vienna, A-1090, Austria
 SO Clin. Exp. Immunol. (1997), 107(3), 536-541
 CODEN: CEXIAL; ISSN: 0009-9104
 PB Blackwell
 DT Journal
 LA English
 CC 15-2 (Immunochemistry)
 AB Several in vitro and in vivo studies indicate that application of high doses of dominant T cell **epitopes** can induce a state of antigen-specific non-responsiveness (anergy). Here, the authors developed a murine model of an allergic immune response to Bet v 1, the major birch pollen allergen. Mice were sensitized by injection of rBet v 1 and the allergic state was proven by the presence of allergen-specific IgE and pos. immediate-type skin tests to Bet v 1. In **epitope** mapping expts., an immunodominant T cell **epitope** of Bet v 1 in BALB/c mice was identified by the use of overlapping peptides. This peptide (BV 139) was subsequently employed for treatment. Two tolerization protocols were used: in one approach, the peptide was administered to naive mice before immunization (group BV 139-S), in the second, already sensitized mice were treated (S-BV 139). The results demonstrated that administering high doses of the dominant T cell **epitope** of Bet v 1 profoundly diminished T cell proliferation to the peptide in the BV 139-S group, and to the peptide as well as to the whole protein in the S-BV 139 group. Skin test reactivity to Bet v 1 was reduced in the BV 139-S group. However, no differences in terms of specific antibody prodn. between treated and untreated mice could be obsd. Thus, administration of dominant T cell **epitopes** can down-regulate the allergen-specific T cell response. Proceeding on the assumption that the T lymphocyte response to allergens is crucial for the induction and maintenance of the allergic disease, a modulation of the immune response to allergens by treatment with T cell **epitope** peptides could represent a promising concept for immunotherapy in the future.
 ST allergy T cell **epitope** birch allergen;
 pollen allergen Betv1 T cell **epitope**
 IT Allergens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Bet v I (Betula verrucosa, I); allergic immune response modulation by s.c. injection of high doses of dominant T cell **epitope** from major birch pollen allergen Bet v 1 in relation to immunotherapy)
 IT Birch
Epitopes
 Immune tolerance
 Immunotherapy
 Pollen
 T cell (lymphocyte)
 (allergic immune response modulation by s.c. injection of high doses of dominant T cell **epitope** from major birch pollen allergen Bet v 1 in relation to immunotherapy)
 IT Hypersensitivity

(immediate hypersensitivity; allergic immune response modulation by s.c. injection of high doses of dominant T cell **epitope** from major birch pollen allergen Bet v 1 in relation to immunotherapy)

IT 188724-41-6

RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (allergic immune response modulation by s.c. injection of high doses of dominant T cell **epitope** from major birch pollen allergen Bet v 1 in relation to immunotherapy)

L5 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1998:12536 CAPLUS

DN 128:87790

TI **Epitope** analysis of birch pollen allergen in Japanese subjects

AU Abe, Yusuke; Kimura, Shoji; Kokubo, Taku; Mizumoto, Keiko; Uehara, Motoharu; Katagiri, Makoto

CS Department of Pathology, Asahikawa Medical College, Asahikawa, 078, Japan

SO J. Clin. Immunol. (1997), 17(6), 485-493

CODEN: JCIMDO; ISSN: 0271-9142

PB Plenum Publishing Corp.

DT Journal

LA English

CC 15-9 (Immunochemistry)

AB Birch pollen is a very common cause of nasal allergy (pollinosis) not only in Scandinavia, Europe, Canada, and the northern part of the United States but also in Hokkaido, Japan. The authors have previously reported a pos. assocn. between the HLA-DR9 phenotype and the development of birch pollen allergy in Japanese subjects. However, there is little information about T cell **epitopes** of birch pollen which are presented by HLA class II mols. other than HLA-DR9. Therefore, the authors analyzed the difference in T cell **epitope** usage in patients who had HLA-DR9 vs. those who did not. Seven Japanese patients with birch pollinosis were studied. Some groups of peptides representing T cell **epitopes** (Betula verrucosa; Bet VI peptides, p7-33, p23-46, p138-160) appeared to be shared by the majority, while another peptide (Bet VI p72-95) was recognized predominantly by patients who expressed HLA-DR9 and/or HLA-DQ3 mols. Moreover, seven T cell clones and eight T cell lines were generated from two patients who did not have HLA-DR9 or HLA-DQ3. Using some of these T cell clones/lines, the authors investigated the relation between HLA class II mols. and antigenic peptides. One of these T cell clones recognized antigenic peptides in the context of the HLA-DQ1 mol. To the authors' knowledge, this is the first indication that the **epitope** on Bet VI can be presented by the HLA-DQ mol.

ST **epitope birch allergen** HLA DQ

IT Allergens

RL: PRP (Properties) (Bet v I (Betula verrucosa, I); **epitope** anal. of birch tree allergen in Japanese humans with pollinosis)

IT HLA-DQ antigen

RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (HLA-DQ1 antigen; **epitope** anal. of birch tree allergen in Japanese humans with pollinosis)

IT **Epitope** mapping

Epitopes

Hay fever

Pollen

T cell (lymphocyte)

(**epitope** anal. of birch tree allergen in Japanese humans with pollinosis)

IT Peptides, biological studies

RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)

(**epitope** anal. of birch tree allergen in Japanese humans with pollinosis)

IT T cell stimulating structure-activity relationship
(of peptides of birch pollen allergen)

IT 201009-61-2 201009-62-3 201009-63-4 201009-64-5 201009-65-6
201009-66-7 201009-67-8 201009-68-9 201009-69-0 201009-70-3
201009-71-4 201009-72-5 201009-73-6 201009-74-7 201009-75-8
201009-76-9 201009-77-0 201009-78-1 201009-79-2 201009-80-5
201009-81-6 201009-82-7 201009-83-8 201009-84-9 201009-85-0
201009-86-1 201009-87-2 201009-88-3 201009-89-4 201009-90-7
201009-91-8 201009-92-9 201009-93-0

RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)

(**epitope** anal. of birch tree allergen in Japanese humans with pollinosis)

L5 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1997:221926 CAPLUS

DN 126:237360

TI Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1

AU Lebecque, Serge; Dolecek, Christiane; Laffer, Sylvia; Visco, Vincenzo; Denepoux, Stephane; Pin, Jean-Jacques; Guret, Christiane;

Boltz-Nitulescu,

George; Weyer, Anne; Valenta, Rudolf

CS Laboratory for Immunological Research, Schering-Plough, Dardilly, 69571, Fr.

SO J. Allergy Clin. Immunol. (1997), 99(3), 374-384

CODEN: JACIBY; ISSN: 0091-6749

PB Mosby-Year Book

DT Journal

LA English

CC 15-9 (Immunochemistry)

AB Bet v 1 and homologous proteins represent major allergens for almost 95% of patients allergic to tree pollen and approx. 70% of those allergic to fruits and vegetables. As yet, no continuous (sequential) IgE **epitopes** have been detd. for Bet v 1, and evidence has accumulated that Bet v 1 IgE **epitopes** belong to the conformational (discontinuous) type. A panel of 85 mouse monoclonal anti-Bet v 1 antibodies was raised as a tool with which to study the interaction of human IgE antibodies with Bet v 1. The **epitopes** of selected monoclonal antibodies (mAbs) were characterized by mapping with synthetic overlapping peptides and by cross-competition expts. Cross-reactivity of Bet v 1-specific mAbs with tree and plant food allergens was investigated by Western blotting. The influence of Bet v 1-specific mAbs on the IgE-Bet v 1 interaction was studied by competition assays with immobilized

purified recombinant Bet v 1 and by basophil histamine release expts.

Antibodies that increased the IgE binding to Bet v 1 up to fivefold could

be defined, whereas others inhibited IgE binding to Bet v 1 up to 99% and competed with the Bet v 1-induced histamine release from patients' basophils. The activity of the enhancing antibodies is interpreted as a stabilization of Bet v 1 state/IgE **epitopes**, which are either more accessible for certain IgE antibodies or are recognized with higher affinity. Those mAbs that competed with the Bet v 1-IgE interaction, if humanized or produced as recombinant antibody fragments, might be considered as potential tools for local allergy therapy.

ST monoclonal antibody allergen Bet v1 IgE

IT Allergens

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(Bet v I (Betula verrucosa, I); effect of monoclonal antibodies on the binding of human IgE to **birch allergen** Bet v 1)

IT Monoclonal antibodies

RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(effect of monoclonal antibodies on the binding of human IgE to **birch allergen** Bet v 1)

IT IgE

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(effect of monoclonal antibodies on the binding of human IgE to **birch allergen** Bet v 1)

IT Basophil

(effect of monoclonal antibodies on the binding of human IgE to **birch allergen** Bet v 1 in relation to histamine release from basophils)

IT 51-45-6, Histamine, biological studies

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(effect of monoclonal antibodies on the binding of human IgE to **birch allergen** Bet v 1 in relation to histamine release from basophils)

L5 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1997:282897 CAPLUS

DN 126:329438

TI Bip 1, a monoclonal antibody with specificity for the major birch pollen allergen Bet v 1, modulates IgE binding to the allergen

AU Laffer, Sylvia; Vangelista, Luca; Steinberger, Peter; Kraft, Dietrich; Pastore, Annalisa; Valenta, Rudolf

CS Institute of General and Experimental Pathology, AKH, University of Vienna, Vienna, A-1090, Austria

SO Int. Arch. Allergy Immunol. (1997), 113(1-3), 260-261
CODEN: IAAIEG; ISSN: 1018-2438

PB Karger

DT Journal

LA English

CC 15-9 (Immunochemistry)

AB Patients allergic to tree pollen, fruit, and vegetables display IgE cross-reactivity to the major birch pollen allergen Bet v 1. In contrast to other major allergens, no continuous IgE **epitopes** have been identified for Bet v 1 as yet, indicating that the **epitopes** are of the conformational type. Previously, the authors produced an antibody,

Bip 1, which was obsd. to enhance IgE binding to Bet v 1. Here, the authors expressed the Bip 1 Fab in Escherichia coli and characterized the purified recombinant Fab and its interaction with Bet v 1 by immunol. and spectroscopic methods.

ST Bip 1 antibody **birch allergen** IgE

IT Allergens
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (Bet v I (Betula verrucosa, I); Bip 1 monoclonal antibody modulates
 human IgE binding to birch pollen group 1 allergen)

IT Birch (Betula pendula)
 Molecular association
 (Bip 1 monoclonal antibody modulates human IgE binding to birch pollen
 group 1 allergen)

IT IgE
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (Bip 1 monoclonal antibody modulates human IgE binding to birch pollen
 group 1 allergen)

IT Monoclonal antibodies
 RL: BAC (Biological activity or effector, except adverse); BIOL
 (Biological study)
 (Bip 1; modulation of human IgE binding to birch pollen group 1
 allergen by)

L5 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1996:548557 CAPLUS

DN 125:193456

TI Immunoassay method and reagent involving suspendable carbon-labeled
 bioaffine particles

IN Loennberg, Maria; Carlsson, Jan

PA Pharmacia Ab, Swed.

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM G01N033-543

ICS G01N033-532

CC 15-1 (Immunochemistry)

Section cross-reference(s): 9, 14

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9622532	A1	19960725	WO 1996-SE42	19960118
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2210794	AA	19960725	CA 1996-2210794	19960118
	AU 9645928	A1	19960807	AU 1996-45928	19960118
	EP 804733	A1	19971105	EP 1996-901591	19960118
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE, IE				
	JP 11505603	T2	19990521	JP 1996-522207	19960118
PRAI	SE 1995-184		19950120		
	WO 1996-SE42		19960118		

AB An anal. method comprises establishing the presence of an analyte in a
 sample by forming a complex between the analyte and its bioaffine
 counterpart and a suspendable bioaffine reactant (R1) which is labeled
 with carbon particles and incorporated in the complex in an amt. related
 to the amt. of analyte in the sample. The method is characterized in

that
 a measurable part of the particles are able to settle. An immunoreagent
 is described that is labeled with particles and chosen from the group

IgE,
 anti-IgE antibody, or allergen, including IgE-reactive **epitopes**
 thereof, characterized in that the particles are carbon particles.

ST immunoassay carbon particle bioaffinity label; allergen specific IgE detn

carbon particle; immunochromatog carbon particle bioaffinity label; blood
allergen IgE detn allergy diagnosis

IT **Birch**
Mite and Tick
(**allergens**; immunoassay method and reagent using suspendable
carbon-labeled bioaffine particles)

IT Allergy
Asthma
Blood analysis
Immunoassay
Inflammation
Polymer-supported reagents
(immunoassay method and reagent using suspendable carbon-labeled
bioaffine particles)

IT Antibodies
RL: ANT (Analyte); ARG (Analytical reagent use); THU (Therapeutic use);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(immunoassay method and reagent using suspendable carbon-labeled
bioaffine particles)

IT Allergens
Antigens
Caseins, biological studies
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL
(Biological study); USES (Uses)
(immunoassay method and reagent using suspendable carbon-labeled
bioaffine particles)

IT Carbon black, uses
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(immunoassay method and reagent using suspendable carbon-labeled
bioaffine particles)

IT Polyamide fibers, analysis
RL: ARU (Analytical role, unclassified); DEV (Device component use); ANST
(Analytical study); USES (Uses)
(immunoassay method and reagent using suspendable carbon-labeled
bioaffine particles)

IT Immunoglobulins
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL
(Biological study); USES (Uses)
(A, immunoassay method and reagent using suspendable carbon-labeled
bioaffine particles)

IT Immunoglobulins
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL
(Biological study); USES (Uses)
(D, immunoassay method and reagent using suspendable carbon-labeled
bioaffine particles)

IT Immunoglobulins
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL
(Biological study); USES (Uses)
(E, immunoassay method and reagent using suspendable carbon-labeled
bioaffine particles)

IT Immunoglobulins
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL
(Biological study); USES (Uses)
(G, immunoassay method and reagent using suspendable carbon-labeled
bioaffine particles)

IT Immunoglobulins
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL
(Biological study); USES (Uses)

(M, immunoassay method and reagent using suspendable carbon-labeled bioaffine particles)

IT Immunoassay
(immunoadsorption chromatog., immunoassay method and reagent using suspendable carbon-labeled bioaffine particles)

IT 9004-70-0, Nitrocellulose
RL: ARU (Analytical role, unclassified); DEV (Device component use); ANST (Analytical study); USES (Uses)
(immunoassay method and reagent using suspendable carbon-labeled bioaffine particles)

IT 7440-44-0, Carbon, uses
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(particles; immunoassay method and reagent using suspendable carbon-labeled bioaffine particles)

L5 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1997:474622 CAPLUS
DN 127:160510
TI Diversity of human T cell receptor sequences of T cell clones with specificity for Bet v 1 peptide/MHC II complexes
AU Breiteneder, Heimo; Hajek, Roswitha; Huttinger, Robert; Ebner, Christof; Schenk, Siegfried; Kraft, Dietrich; Scheiner, Otto
CS Institute of General and Experimental Pathology, AKH-EBO-3Q, University of Vienna, Vienna, 1090, Austria
SO Adv. Exp. Med. Biol. (1996), 409 (New Horizons in Allergy Immunotherapy), 365-374
CODEN: AEMBAP; ISSN: 0065-2598
PB Plenum
DT Journal
LA English
CC 15-9 (Immunochemistry)
AB T cell clones (TCC) were raised from the peripheral blood of patients suffering from tree pollen allergy. All TCC were restricted by HLA-DR mols. To investigate possible intervention targets in type I allergic diseases, the authors examd. T cell receptor (TCR) .alpha.- and .beta.-chain nucleotide sequences of several allergen-reactive human CD4+ TCC specific for 4 frequently found **epitopes** of Bet v 1, the major birch pollen allergen. In general, TCC specific for the 4 **epitopes** investigated, used diverse TCRAV and TCRBV gene segments. Moreover, the junctional regions encoding the third complementarity detg. regions (CDR3) of the TCR showed striking heterogeneities in length and amino acid compn. A more restricted use of two J gene segments (TCRBJ1S4 and 2S7) was only obsd. in the .beta.-chain of TCR used by TCC specific for **epitope** 1. In addn., all TCC specific for **epitope** 4 showed an arginine residue in the N-terminal region of their TCRBV CDR3 loops despite their sequence diversities. In view of the striking heterogeneities found, therapeutic strategies aimed at the clonal deletion of allergen-specific T cell clones, providing help for IgE synthesis, may not be feasible. Moreover, these results cast a doubt on the theory, that the CDR3 exclusively provides the primary contact with the peptide bound in the major histocompatibility (MHC) groove, and suggest addnl. interaction with MHC class II.
ST TCR usage T cell **birch allergen**
IT Allergens
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(Bet v I (Betula verrucosa, I); TCR receptor usage by HLA-DR-restricted human T cells specific for birch pollen allergen **epitopes**)

IT CD4-positive T cell
DNA sequences
Epitopes
Pollen
Protein sequences
(TCR receptor usage by HLA-DR-restricted human T cells specific for birch pollen allergen **epitopes**)

IT HLA-DR antigen
TCR .alpha..beta. (receptor)
RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
(TCR receptor usage by HLA-DR-restricted human T cells specific for birch pollen allergen **epitopes**)

IT 150302-77-5 150302-78-6 167382-53-8 187540-70-1
RL: PRP (Properties)
(TCR receptor usage by HLA-DR-restricted human T cells specific for birch pollen allergen **epitopes**)

L5 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1996:355269 CAPLUS
DN 125:31847
TI Evidence for an alpha helical T cell **epitope** in the C-terminus of the main birch pollen allergen Bet v 1
AU Kungl, Andreas J.; Susani, Markus; Lindemann, Almut; Machius, Mischa; Visser, Antonie J. W. G.; Scheiner, Otto; Kraft, Dietrich; Breitenbach, Michael; Auer, Manfred
CS Department Immunodermatology, Sandoz Research Institute, Vienna, A-1235, Austria
SO Biochem. Biophys. Res. Commun. (1996), 223(1), 187-192
CODEN: BBRC9; ISSN: 0006-291X
DT Journal
LA English
CC 15-9 (Immunochemistry)
Section cross-reference(s): 11

AB Secondary structure prediction of the main birch pollen allergen Bet v 1 was in good agreement with the secondary structural elements found by analyzing the Bet v 1 CD data. According to both expt. and prediction, 32% of 160 amino acids participate in alpha helixes, 21% in beta sheets, 24% in turns, and 23% in other structural motifs. The peptide LRAVESYLLAHS which represents one of the major T cell **epitopes** on Bet v 1 was shown to have a high propensity to form an alpha helix. Time-resolved fluorescence anisotropy measurements of the allergen revealed an overall rotational correlation time of 7.35 ns, which corresponds to a hydrodynamic mol. radius of 19.2 .ANG.. This refers to

a monomeric Bet v 1 mol. in soln., which is also reflected in the narrow band width of the 1H-NMR spectrum. The results presented here are in

good agreement with the recently solved NMR structure of Amb t 5; both allergens are monomers in soln. with an extended C-terminal alpha helix contg. a major T cell **epitope**.

ST **birch allergen Betv1 epitope** alpha helix; T lymphocyte **birch allergen Betv1 epitope**

IT Conformation and Conformers
Pollen

Protein sequences
(alpha helical human T cell **epitope** in C-terminus of main
birch pollen allergen Bet v 1)

IT Allergens
RL: BOC (Biological occurrence); PRP (Properties); BIOL (Biological
study); OCCU (Occurrence)
(Bet v I (Betula verrucosa, I), alpha helical human T cell
epitope in C-terminus of main birch pollen allergen Bet v 1)

IT Lymphocyte
(T-cell, alpha helical human T cell **epitope** in C-terminus of
main birch pollen allergen Bet v 1)

IT Conformation and Conformers
(.alpha.-helical, alpha helical human T cell **epitope** in
C-terminus of main birch pollen allergen Bet v 1)

IT 151901-17-6
RL: BOC (Biological occurrence); PRP (Properties); BIOL (Biological
study); OCCU (Occurrence)
(T-cell **epitope**; alpha helical human T cell **epitope**
in C-terminus of main birch pollen allergen Bet v 1)

L5 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1996:546462 CAPLUS
DN 125:219490
TI High-level expression in Escherichia coli and purification of recombinant
plant profilins: comparison of IgE-binding capacity and allergenic
activity
AU Vrtala, Susanne; Wiedemann, Petra; Mittermann, Irene; Eichler,
Hans-Georg;
Sperr, Wolfgang R.; Valent, Peter; Kraft, Dietrich; Valenta, Rudolf
CS Inst. Generla Experimental Pathology, Univ. Vienna, Austria
SO Biochem. Biophys. Res. Commun. (1996), 226(1), 42-50
CODEN: BBRCA9; ISSN: 0006-291X
DT Journal
LA English
CC 15-9 (Immunochemistry)
AB Because of their structural similarity and ubiquitous distribution as
actin binding proteins, plant profilins represent important
cross-reactive
allergens for almost 20% of patients suffering from Type I allergy to
pollen and other plant products. The cDNAs coding for three birch
profilin variants (Tyr44, Glu47, and Asn47), timothy grass profilin, and
three tobacco profilin isoforms (ntprofil-3) were expressed at high levels
in Escherichia coli as a non-fusion proteins. The recombinant plant
profilins were purified to homogeneity by poly (L-proline) affinity
chromatog. and showed comparable capacity to bind IgE-antibodies from
profilin allergic patients. All recombinant plant profilins elicited
dose-dependent histamine release from basophils of a profilin allergic
patient and induced immediate type skin reactions. It is concluded that
profilins from different plant species share IgE-**epitopes** and
allergenic properties. Plant profilins therefore constitute a family of
functional pan-allergens which may substitute each other for diagnosis
and
specific immunotherapy.

ST profilin allergen IgE binding
IT Allergens
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(Bet v 2 (Betula verrucosa, 2); **birch allergen**
binding by IgE from allergic humans)

IT Basophil
(IgE-binding capacity and allergenic activity of recombinant profilins from birch, timothy grass, and tobacco pollen in relation to histamine release by basophils)

IT Allergy
(birch, timothy grass, and tobacco profilin binding by IgE from allergic humans)

IT Birch
Escherichia coli
Timothy
Tobacco
(high-level expression in Escherichia coli and comparison of IgE-binding capacity and allergenic activity of recombinant profilins from birch, timothy grass, and tobacco pollen)

IT Profilins
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
(high-level expression in Escherichia coli and comparison of IgE-binding capacity and allergenic activity of recombinant profilins from birch, timothy grass, and tobacco pollen)

IT Immunoglobulins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(E, high-level expression in Escherichia coli and comparison of IgE-binding capacity and allergenic activity of recombinant profilins from birch, timothy grass, and tobacco pollen)

IT 51-45-6, Histamine, biological studies
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(IgE-binding capacity and allergenic activity of recombinant profilins from birch, timothy grass, and tobacco pollen in relation to histamine release by basophils)

L5 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1995:645495 CAPLUS

DN 123:141599

TI Multiplicity of cross-reactive **epitopes** on Bet v I as detected with monoclonal antibodies and human IgE

AU Akkerdaas, J. H.; van Ree, R.; Aalbers, M.; Stapel, S. O.; Aalberse, R. C.

CS Central Laboratory, Netherlands Red Cross Blood Transfusion Service, Amsterdam, 1066 CX, Neth.

SO Allergy (Copenhagen) (1995), 50(3), 215-20
CODEN: LLRGDY; ISSN: 0105-4538

DT Journal

LA English

CC 15-9 (Immunochemistry)

Section cross-reference(s): 17

AB Six monoclonal antibodies against Bet v I, the major cross-reactive allergen of birch pollen (*Betula verrucosa*), were obtained. Four did not react with fruits, but 2 monoclonal antibodies (mAbs) (5H8 and 9C11) were reactive with apple and other fruits. These 2 cross-reactive antibodies reacted with identical or overlapping sites, but differed in their relative degree of cross-reactivity toward various fruits and hazelnut. Cross-reactive human IgE antibodies reacted with a non-overlapping **epitope**, as indicated by results of a 2-site RIA with the fruit-reactive mAb 9C11. By isoelec. focusing (IEF) in conjunction with immunoblotting, a max. of 7 isoforms could be distinguished. Depletion

of

birch-pollen ext. for Bet v I with the most reactive mAb (7F7) removed approx. 95% of the IgE cross-reactivity between birch pollen and apple ext. The remaining 5% cross-reactive material still could inhibit the binding of IgE to apple allergen completely, and was reactive with mAbs 5H8 and 3C4. By IEF/immunoblot, it was shown that these mAbs recognize

an isoform of Bet v I that is poorly, if at all, recognized by mAb 7F7. These results illustrate the heterogeneity of Bet v I, both with respect to the cross-reactive sites as well as to the backbone structure. This type of heterogeneity has possible implications for the use of monoclonal antibodies in allergen standardization.

ST crossreactive **epitope birch allergen**
 antibody IgE

IT Alder
 Apple
 Birch
 Cherry
 Hazel
 Peach
 Pear
 (multiplicity of cross-reactive **epitopes on birch allergen** as detected with monoclonal antibodies and human IgE)

IT Allergens
 RL: PRP (Properties)
 (Bet v I (Betula verrucosa, I), multiplicity of cross-reactive **epitopes on birch allergen** as detected with monoclonal antibodies and human IgE)

IT Immunoglobulins
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (E, multiplicity of cross-reactive **epitopes on birch allergen** as detected with monoclonal antibodies and human IgE)

IT Antibodies
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (monoclonal, multiplicity of cross-reactive **epitopes on birch allergen** as detected with monoclonal antibodies and human IgE)

L5 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2000 ACS
 AN 1995:724208 CAPLUS
 DN 123:167018
 TI Diversity of TCRAV and TCRBV sequences used by human T-cell clones specific for a minimal **epitope** of Bet v 1, the major birch pollen allergen
 AU Breiteneder, Heimo; Scheiner, Otto; Hajek, Roswitha; Hulla, Wolfgang; Huettinger, Robert; Fischer, Gottfried; Kraft, Dietrich; Ebner, Christof
 CS Institute of General and Experimental Pathology, University of Vienna, Vienna, A-1090, Austria
 SO Immunogenetics (1995), 42(1), 53-8
 CODEN: IMNGBK; ISSN: 0093-7711
 DT Journal
 LA English
 CC 15-2 (Immunochemistry)
 Section cross-reference(s): 3
 AB T-cell clones (TCC) were raised from the peripheral blood of patients suffering from tree pollen allergy. All TCC were restricted by HLA-DR mols. To investigate possible intervention targets in Type I allergic

diseases, the authors examd. T-cell receptor (TCR) .alpha. and .beta. chain nucleotide sequences of five allergen-reactive human CD4+ TCC specific for a C-terminal **epitope** (BV 144) of Bet v 1, the major birch pollen allergen. Proliferation assays using synthetic peptides revealed the 10-mer LRAVESYLLA as minimal **epitope** for three TCC; two TCC also displayed reactivity with the nonapeptide LRAVESYLL. Two

TCC

expressed TCRBV2S3, all other BV144-specific TCC used diverse TCRAV and TCRBV gene segments. Moreover, the junctional regions encoding the third complementary detg. regions (CDR3) of the TCR showed a striking heterogeneity in length and amino acid compn. Nevertheless, all TCC showed an arginine residue in the N-terminal region of their TCRBV CDR3 loops. Therefore, therapeutic strategies aimed at the clonal deletion of allergen-specific T-cell clones, providing help for IgE synthesis, will not be feasible. The results cast a doubt on the theory that the CDR3 exclusively provides the primary contact with the peptide bound in the major histocompatibility (MHC) groove, and suggest addnl. interaction

with

MHC class II.

ST TCR alphabeta V region **birch allergen**; Betv1 allergen

TCR alphabeta V region; gene TCRAV TCRBV diversity Betv1 allergen

IT Gene, animal

RL: PRP (Properties)

(TCRAV11S1J6C; diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Gene, animal

RL: PRP (Properties)

(TCRAV2S3J17S7C; diversity of T-cell receptor TCRAV and TCRBV

sequences

used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Gene, animal

RL: PRP (Properties)

(TCRAV5S1J21C; diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Gene, animal

RL: PRP (Properties)

(TCRAV8S1J9S5C; diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Gene, animal

RL: PRP (Properties)

(TCRAV8S2J9S15C; diversity of T-cell receptor TCRAV and TCRBV

sequences

used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Gene, animal

RL: PRP (Properties)

(TCRAV9S1J9S3C; diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Gene, animal

RL: PRP (Properties)

(TCRBV15S1D1J2S5C2; diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Gene, animal
 RL: PRP (Properties)
 (TCRBV17S1D1J2S3C2; diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Gene, animal
 RL: PRP (Properties)
 (TCRBV24S1D1J2S2C2; diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Gene, animal
 RL: PRP (Properties)
 (TCRBV2S3D1J1S5C1; diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Gene, animal
 RL: PRP (Properties)
 (TCRBV2S3D2J2S1C2; diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Birch
 (B. pendula, diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Allergens
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BIOL (Biological study); PROC (Process)
 (Bet v I (Betula verrucosa, I), diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Immunoglobulins
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (E, diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Histocompatibility antigens
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BIOL (Biological study); PROC (Process)
 (HLA-DR, diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Lymphocyte
 (T-cell, diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Antigen receptors
 Receptors
 RL: PRP (Properties)
 (TCR (T-cell antigen receptor), diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Antigen receptors
 Receptors
 RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence); BPR (Biological process); PRP (Properties); BIOL (Biological study); OCCU

(Occurrence); PROC (Process)

(TCR .alpha..beta. (T-cell antigen receptor .alpha..beta.), diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT Deoxyribonucleic acid sequences

(complementary, diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT 167382-53-8 167382-54-9

RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BIOL (Biological study); PROC (Process)

(as **epitope** for T-cell; diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

IT 164272-40-6, Genbank Z47366 164272-41-7, Genbank Z47367 164272-42-8, Genbank Z47368 164272-43-9, Genbank Z47369 164272-44-0, Genbank Z47371

164272-45-1, Genbank Z47370 164272-46-2, Genbank Z47372 164272-47-3, Genbank Z47373 164272-48-4, Genbank Z47374 164272-49-5, Genbank Z47375

164272-50-8, Genbank Z47376

RL: PRP (Properties)

(nucleotide sequence; diversity of T-cell receptor TCRAV and TCRBV sequences used by human T-cell clones specific for minimal **epitope** of Bet v 1, major birch pollen allergen)

L5 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1994:506526 CAPLUS

DN 121:106526

TI Peptides of the main allergens contained in the pollen of trees of the Fagales order for use in diagnosing or treating allergies

IN Ebner, Christof; Ferreira, Fatima; Schenk, Siegfried; Szepefalusi, Zsolt; Valenta, Rudolf; Breitenbach, Michael; Kraft, Dietrich; Rumpold, Helmut; Scheiner, Otto

PA Biomay Produktions- und Handelsgesellschaft m.b.H., Austria

SO PCT Int. Appl., 11 pp.

CODEN: PIXXD2

DT Patent

LA German

IC ICM C07K007-08

ICS A61K039-36; G01N033-68

CC 15-9 (Immunochimistry)

FAN, CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9410194	A2	19940511	WO 1993-AT163	19931025
	WO 9410194	A3	19940901		
	W: AU, CA, FI, JP, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9454115	A1	19940524	AU 1994-54115	19931025
PRAI	AT 1992-2125		19921027		
	AT 1993-43		19930114		
	WO 1993-AT163		19931025		

AB The invention concerns the T-cell **epitope** of a 17 kD protein present as the main allergen contained in the pollen of trees of the Fagales order, in particular birches, hazels and alders, or generated by genetic engineering as a recombinant protein. Because of the high degree

of affinity between said trees, their resp. 17 kD proteins are also highly homologous. These proteins are designed as Bet v I, Cor a I and Aln g I in the international literature and cause tree pollen allergies in predisposed persons (allergic patients). The peptides derived from the main allergens (major allergens), in particular Bet v I, are suitable for diagnosing tree pollen allergy and are capable of stimulating (causing the proliferation, the cytokine prodn.) or blocking T-cells of the patients in vitro and in vivo in an allergen-specific manner, or to provoke tolerance to the allergen specific T-cells. Peptides of Bet v I which stimulate T cells from patients allergic to birch trees were identified. The crossreactivity of T cells from patients allergic to hazels and alders with these peptides was significant.

ST **birch allergen** Bet v I peptide; allergy diagnosis
 treatment **birch allergen** peptide
 IT Allergens
 RL: BIOL (Biological study)
 (Aln g I, peptides of, for diagnosis and treatment of allergies)
 IT Allergy
 (diagnosis of, peptides of primary allergen of Fagales trees for)
 IT Allergy inhibitors
 (peptides of primary allergen of Fagales trees as)
 IT Alder
 (primary allergen Aln g I of, peptides of, for diagnosis and treatment of allergies)
 IT Birch
 (primary allergen Bet v I of, peptides of, for diagnosis and treatment of allergies)
 IT Hazel
 (primary allergen Cor a I of, peptides of, for diagnosis and treatment of allergies)
 IT Fagales
 (primary allergen of, peptides of, for diagnosis and treatment of allergies)
 IT Allergens
 RL: BIOL (Biological study)
 (Bet v I (Betula verrucosa, I), peptides of, for diagnosis and treatment of allergies)
 IT Allergens
 RL: BIOL (Biological study)
 (Cor a I (Corylus avellana, I), peptides of, for diagnosis and treatment of allergies)
 IT 150302-72-0, Allergen Bet v I(1-16) (birch) 150302-73-1, Allergen Bet v I(35-48) (birch) 150302-74-2, Allergen Bet v I(75-90) (birch) 150302-79-7, Allergen Bet v I (111-126) (birch) 150321-14-5, Allergen Bet v I(29-44) (birch) 152647-59-1, Allergen Bet v I (141-159) (birch) 156880-97-6, Allergen Bet v I(9-26) (birch) 156880-98-7, Allergen Bet v I(61-76) (birch) 156880-99-8, Allergen Bet v I(84-97) (birch) 156881-00-4, Allergen Bet v I (93-110) (birch)
 RL: BIOL (Biological study)
 (T-cell **epitope** of Bet v I allergen, for allergy diagnosis and treatment)

L5 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2000 ACS
 AN 1993:595664 CAPLUS
 DN 119:195664

TI Histamine derivatives and methods for their use as immunomodulators
 IN Melmon, Kenneth L.; Greenstein, Julia L.; Khosropour, Parisa
 PA Immulogic Pharmaceutical Corp., USA; Leland Stanford Junior University
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-415
 ICS A61K039-35; A61K039-39
 CC 1-7 (Pharmacology)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9314754	A1	19930805	WO 1993-US659	19930125
	W: AU, CA, FI, JP, KP, KR, NO, NZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CN 1079908	A	19931229	CN 1993-102513	19930122
	AU 9335915	A1	19930901	AU 1993-35915	19930125
	EP 626847	A1	19941207	EP 1993-904613	19930125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE	JP 07503470	T2	19950413	JP 1993-513377	19930125
PRAI	US 1992-826180		19920127		
	WO 1993-US659		19930125		
AB	Methods are provided for using histamine derivs. His-NH(CH ₂) _n CONHC6H ₄ CF ₃ (n = 2-10) as immunomodulators and in immunotherapeutics. More specifically, methods are provided for inhibiting at least a portion of an antigen-specific antibody response and/or a portion of a T-cell proliferative response by the immune system of a mammal, comprising administering to the mammal an effective amt. of a compn. comprising .gtoreq.1 histamine deriv. having binding specificity for .gtoreq.1 histamine receptor. Also disclosed are methods for treating sensitivity to a particular antigen and methods of treated T-cell-mediated disease in a person by administering a therapeutically effective amt. of a compn. comprising .gtoreq.1 histamine deriv. having binding specificity for .gtoreq.1 histamine receptor, optionally administering the antigen or an immunogenic portion thereof, and further optionally administering a peptide comprising .gtoreq.1 T-cell epitope of the antigen. Examples showed that histamine congeners are potent immunosuppressants, and that each has a different potential mechanism of immunomodulation. His-NHCH(CH ₃)(CH ₂) ₄ CONHC6H ₄ CF ₃ suppresses T-cell-dependent IgE and IgG1 (but not IgM, IgG2a, or IgG2b) antibody responses. His-NH(CH ₂) ₅ CONHC6H ₄ CF ₃ (I) suppresses IgG1, IgG2a, and IgG2b (but not IgM) responses. Only I appears to directly suppress T-cell proliferation to specific antigen at the doses tested. Effects of the derivs. in an autoimmune disease model are presented.				
ST	immunosuppressant histamine deriv				
IT	Antigens				
	RL: BIOL (Biological study)				
	(T-cell antigen-specific proliferative response inhibition by histamine deriv. and)				
IT	Alder				
	Alternaria				
	Artemisia				
	Birch				
	Blattella				

Canidae
 Cryptomeria
 Dermatophagoides
 Felis
 Honeybee
 Lolium
 Oak
 Olea
 Parietaria
 Periplaneta
 Plantago
 Ragweed
 (allergen protein of, sensitivity to, treatment of, histamine
 derivs. for)
 IT Poisoning
 (endotoxin-induced, treatment of, immunosuppressant histamine derivs.
 for)
 IT Allergy inhibitors
 Immunosuppressants
 (histamine derivs.)
 IT Antidiabetics and Hypoglycemics
 (immunosuppressant histamine derivs.)
 IT Peptides, biological studies
 RL: BIOL (Biological study)
 (of allergen T-cell **epitope**, histamine deriv. and, for
 inhibition of allergen-specific antibody response)
 IT Transplant and Transplantation
 (rejection of, treatment of, immunosuppressant histamine derivs. for)
 IT Lymphocyte
 (T-cell, antigen-specific proliferative response of, inhibition of,
 histamine derivs. for)
 IT Neoplasm inhibitors
 (T-cell leukemia, immunosuppressant histamine derivs.)
 IT Antigens
 RL: BIOL (Biological study)
 (auto-, sensitivity to, treatment of, histamine derivs. for)
 IT Allergy inhibitors
 (desensitizers, histamine derivs.)
 IT Toxins
 RL: BIOL (Biological study)
 (endo-, poisoning induced by, treatment of, immunosuppressant
 histamine
 derivs. for)
 IT Receptors
 RL: BIOL (Biological study)
 (histaminic, histamine derivs. binding to, for immunosuppressants)
 IT Therapeutics
 (immuno-, histamine derivs., for T-cell mediated diseases)
 IT Skin, neoplasm
 (mycosis fungoides, treatment of, immunosuppressant histamine derivs.
 for)
 IT 150436-86-5 150643-50-8 150643-51-9 150643-52-0 150643-59-7
 150643-60-0 150643-61-1 150643-62-2 150643-63-3
 RL: BIOL (Biological study)
 (as immunosuppressant)
 IT 51-45-6D, Histamine, derivs.
 RL: BIOL (Biological study)
 (as immunosuppressants)

IT 150436-88-7
 RL: BIOL (Biological study)
 (histamine receptor binding by and immunosuppressant activity of)
 IT 150436-87-6
 RL: BIOL (Biological study)
 (histamine receptor binding by, immunosuppressant histamine derivs. in
 relation to)

L5 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2000 ACS
 AN 1993:493527 CAPLUS
 DN 119:93527
 TI Recombitope peptides containing T cell **epitopes** and stimulating
 T cell activity, for allergy therapy and diagnosis
 IN Rogers, Bruce L.; Morgenstern, Jay P.; Bond, Julian F.; Garman, Richard
 D.; Kuo, Mei Chang; Morville, Malcolm
 PA Immulogic Pharmaceutical Corp., USA
 SO PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C12N015-12
 ICS A61K039-35; C12N015-62; G01N033-53; C07K007-10; C07K015-08;
 A61K039-36
 CC 15-9 (Immunochemistry)
 FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9308280	A1	19930429	WO 1992-US8694	19921016
	W: AU, CA, FI, HU, JP, KR, NO				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	US 5547669	A	19960820	US 1991-807529	19911213
	ZA 9208000	A	19930426	ZA 1992-8000	19921016
	AU 9227940	A1	19930521	AU 1992-27940	19921016
	AU 682658	B2	19971016		
	ZA 9208001	A	19930622	ZA 1992-8001	19921016
	EP 610335	A1	19940817	EP 1992-922494	19921016
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
	JP 07503362	T2	19950413	JP 1992-507748	19921016
	WO 9424281	A1	19941027	WO 1993-US3471	19930414
	W: AU, CA, FI, JP, KR, NO, NZ, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9341026	A1	19941108	AU 1993-41026	19930414
	AU 680820	B2	19970814		
	EP 694067	A1	19960131	EP 1993-910592	19930414
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE					
	JP 09501043	T2	19970204	JP 1993-523074	19930414
	NO 9401370	A	19940608	NO 1994-1370	19940415
	FI 9401758	A	19940616	FI 1994-1758	19940415
	FI 9504895	A	19951013	FI 1995-4895	19951013
	NO 9504095	A	19951213	NO 1995-4095	19951013
	FI 9603331	A	19960827	FI 1996-3331	19960827
PRAI	US 1991-777859		19911016		
	US 1991-807529		19911213		
	US 1989-431565		19891103		
	US 1991-662276		19910228		
	WO 1992-US8694		19921016		
	WO 1993-US3471		19930414		

FI 1995-4895 19951013

AB Recombitope peptides, stimulating T cell activity and comprising .gtoreq.2

T cell **epitopes** derived from the same or from different protein antigens, are provided. The peptides can be derived from protein allergens, autoantigens, or other protein antigens. Methods of diagnosing sensitivity to an allergen or other protein antigen, methods to treat such sensitivity, methods for designing recombitorpe peptides where the protein antigen has unknown or ill-defined T cell **epitopes**, and therapeutic compns. are also disclosed. T cell epitopic studies were done with peptides and protein chains of the human T cell-reactive feline protein (TRFP) and immunoreactive regions were identified. Synthetic oligonucleotides were designed with Escherichia coli-preferred codons for PCR amplification and expression in E. coli of recombitorpe peptides from TRFP. The peptide sequences included a 6 His residue leader sequence

(for allowing purifn. of the expressed recombitorpe peptide using QIAGEN NTA-agarose) and a thrombin cleavage site before the actual recombitorpe sequence. Recombitorpe peptide arrangements were identified which had little to no binding to IgE and which gave responses to T cells of patients allergic to TRFP.

ST recombitorpe peptide T lymphocyte stimulation **epitope**; allergen recombitorpe peptide T cell stimulation; autoantigen recombitorpe peptide T cell stimulation; antigen recombitorpe peptide T cell stimulation; allergy diagnosis treatment recombitorpe peptide; cat allergy recombitorpe peptide; T cell reactive feline protein recombitorpe

IT Allergens

RL: BIOL (Biological study)

(T cell **epitopes** of, in recombitorpe peptides stimulating T cells)

IT Allergy inhibitors

(T cell **epitopes**-contg. T cell-stimulating recombitorpe peptides as)

IT Allergy

(T cell **epitopes**-contg. T cell-stimulating recombitorpe peptides for detection and modification of)

IT Antigens

RL: BIOL (Biological study)

(T cell **epitopes**-contg. T cell-stimulating recombitorpe peptides from, designing of)

IT Proteins, specific or class

RL: BIOL (Biological study)

(TRFP (human T cell-reactive feline protein), T cell **epitopes** of, T cell-stimulating recombitorpe peptides contg.)

IT Alder

Alternaria

Artemisia

Birch

Blattella

Canidae

Cryptomeria

Dermatophagoides

Dermatophagoides farinae

Dermatophagoides pteronyssinus

Felidae

Honeybee
 Lolium
 Oak
 Olea
 Parietaria
 Periplaneta
 Plantago
 Ragweed
 (allergen of, T cell **epitopes** of, in recombitope
 peptides stimulating T cells)
 IT Blood analysis
 (detection of T cells and Igs to protein antigen in, recombitope
 peptides contg. T cell **epitopes** and T cell-stimulating
 activity for)
 IT Immunoglobulins
 RL: BIOL (Biological study)
 (detection of T cells and, to protein antigen, recombitope peptides
 contg. T cell **epitopes** and T cell-stimulating activity for)
 IT Nucleic acids
 RL: BIOL (Biological study)
 (for T cell **epitopes**-contg. T cell-stimulating recombitope
 peptides)
 IT Protein sequences
 (of T cell-stimulating recombitope peptides of human T cell-reactive
 feline protein of cat)
 IT Proteins, biological studies
 RL: BIOL (Biological study)
 (of basement membrane, as autoantigens, T cell **epitopes**
 -contg. T cell-stimulating recombitope peptides from)
 IT Receptors
 RL: BIOL (Biological study)
 (of thyroid cells, as autoantigen, T cell **epitopes**-contg. T
 cell-stimulating recombitope peptides from)
 IT Basement membrane
 (proteins of, as autoantigen, T cell **epitopes**-contg. T
 cell-stimulating recombitope peptides from)
 IT Thyroid gland, composition
 (proteins or receptors of, as autoantigens, T cell **epitopes**
 -contg. T cell-stimulating recombitope peptides from)
 IT Peptides, biological studies
 RL: BIOL (Biological study)
 (recombitopes, T cell **epitopes** on and T cell stimulating)
 IT Felis catus
 (sensitivity to, treatment of, T cell **epitopes**-contg. T
 cell-stimulating recombitope peptides for)
 IT Multiple sclerosis
 (treatment of, with T cell **epitopes**-contg. T cell-stimulating
 recombitope peptides from myelin basic protein of human)
 IT Allergens
 RL: BIOL (Biological study)
 (Lol p I (Lolium perenne, I), recombitope peptide contg. region of,
 for
 T cell stimulation)
 IT Allergens
 RL: BIOL (Biological study)
 (Lol p IX (Lolium perenne, IX), recombitope peptide contg. region of,
 for T cell stimulation)
 IT Allergens

RL: BIOL (Biological study)
 (Amb a I.4 (Ambrosia artemisifolia, I.4), recombiteope peptide contg.
 region of, for T cell stimulation)

IT Allergens
 RL: BIOL (Biological study)
 (Amb a II (Ambrosia artemisifolia, II), recombiteope peptide contg.
 region of, for T cell stimulation)

IT Immunoglobulins
 RL: BIOL (Biological study)
 (E, T cell-stimulating recombiteope peptides contg. T cell
epitopes not stimulating)

IT Phospholipoproteins
 RL: BIOL (Biological study)
 (MBP (myelin basic protein), as autoantigen, T cell **epitopes**
 -contg. T cell-stimulating recombiteope peptides from)

IT Blood-group substances
 RL: BIOL (Biological study)
 (Rh, as autoantigen, T cell **epitopes**-contg. T
 cell-stimulating recombiteope peptides from)

IT Lymphocyte
 (T-cell, recombiteope peptides with **epitopes** for and
 stimulating)

IT Antigens
 RL: BIOL (Biological study)
 (auto-, T cell **epitopes**-contg. T cell-stimulating recombiteope
 peptides from)

IT Receptors
 RL: BIOL (Biological study)
 (cholinergic, as autoantigen, T cell **epitopes**-contg. T
 cell-stimulating recombiteope peptides from)

IT Deoxyribonucleic acid sequences
 (complementary, for human T cell-reactive feline protein of cat,
 recombiteope peptides prepn. in relation to)

IT Allergy
 (delayed hypersensitivity, detection of, T cell **epitopes**
 -contg. T cell-stimulating recombiteope peptides for)

IT Allergy
 (immediate hypersensitivity, detection of, T cell **epitopes**
 -contg. T cell-stimulating recombiteope peptides for)

IT Allergens
 RL: BIOL (Biological study)
 (Der f I (Dermatophagoides farinae, I), recombiteope peptide contg.
 region of, for T cell stimulation)

IT Allergens
 RL: BIOL (Biological study)
 (Der f II (Dermatophagoides farinae, II), recombiteope peptide contg.
 region of, for T cell stimulation)

IT Allergens
 RL: BIOL (Biological study)
 (Der p I (Dermatophagoides pteronyssinus, I), recombiteope peptide
 contg. region of, for T cell stimulation)

IT Allergens
 RL: BIOL (Biological study)
 (Der p II (Dermatophagoides pteronyssinus, II), recombiteope peptide
 contg. region of, for T cell stimulation)

IT Allergens
 RL: BIOL (Biological study)
 (Amb a I (Ambrosia artemisifolia, I), recombiteope peptide contg.
 region

of, for T cell stimulation)

IT Allergens
RL: BIOL (Biological study)
(Amb a I.1 (Ambrosia artemisifolia, I.1), recombiteope peptide contg. region of, for T cell stimulation)

IT Allergens
RL: BIOL (Biological study)
(Amb a I.2 (Ambrosia artemisifolia, I.2), recombiteope peptide contg. region of, for T cell stimulation)

IT Allergens
RL: BIOL (Biological study)
(Amb a I.3 (Ambrosia artemisifolia, I.3), recombiteope peptide contg. region of, for T cell stimulation)

IT Allergens
RL: BIOL (Biological study)
(Cry j I (Cryptomeria japonica, I), recombiteope peptide contg. region of, for T cell stimulation)

IT Allergens
RL: BIOL (Biological study)
(Cry j II, recombiteope peptide contg. region of, for T cell stimulation)

IT 136796-96-8, Leader A-human T cell-reactive feline protein chain 1 (cat)
136796-97-9, Leader B-human T cell-reactive feline protein chain 1 (cat)
144996-55-4, Human T cell-reactive feline protein chain 2 (cat)
RL: BIOL (Biological study)
(amino acid sequence of and T cell **epitopes**-contg. T cell-stimulating recombiteope peptides recombinant prepn. in relation to)

IT 9004-10-8, Insulin, biological studies 9024-58-2 81876-95-1, Carboxypeptidase H
RL: BIOL (Biological study)
(as autoantigen, T cell **epitopes**-contg. T cell-stimulating recombiteope peptides from)

IT 149013-73-0
RL: BIOL (Biological study)
(as leader sequence in purifn. and prepn. of recombiteope peptide from human T cell-reactive feline protein)

IT 149119-96-0 149119-97-1 149120-00-3
RL: BIOL (Biological study)
(nucleotide sequence of and T cell **epitopes**-contg. T cell-stimulating recombiteope peptides recombinant prepn. in relation to)

IT 136380-69-3, Human T cell-reactive feline protein chain 1 (29-55) (cat synthetic) 136380-84-2, Human T cell-reactive feline protein chain 2 (14-39) (cat synthetic) 136380-92-2, Human T cell-reactive feline protein chain 1 Fel-29 fragments (cat synthetic) 149013-72-9 149230-58-0, Human T cell-reactive feline protein chain 1 (7-33) (cat synthetic) 149230-59-1, Human T cell-reactive feline protein chain 1 fragments (cat synthetic)
RL: BIOL (Biological study)
(recombiteope peptide contg., cat allergy detection and treatment with)

IT 9002-04-4, Thrombin
RL: BIOL (Biological study)
(synthetic leader sequence cleavage with, in prepn. of recombiteope peptide from human T cell-reactive feline protein)

DN 120:29263

TI T cell clones specific for Bet v I, the major birch pollen allergen, crossreact with the major allergens of hazel, Cor a I, and alder, Aln g I

AU Ebner, Christof; Ferreira, Fatima; Hoffmann, Karin; Hirschwehr, Reinhold; Schenk, Siegfried; Szepefalusi, Zsolt; Breiteneder, Heimo; Parronchi, Paola; Romagnani, Sergio; et al.

CS Inst. Gen. Exp. Pathol., Univ. Vienna, Austria

SO Mol. Immunol. (1993), 30(15), 1323-9
CODEN: MOIMD5; ISSN: 0161-5890

DT Journal

LA English

CC 15-9 (Immunochemistry)

AB Tree pollens are responsible for type I allergies during the flowering season in spring. Pollens from birch, hazel and alder constitute the most important allergen sources in this respect in the northern hemisphere. Human IgE antibodies, specific for the major allergens of these pollens, are known to crossreact, and in general every tree pollen allergic patient is sensitized to these three pollen allergens. In this study the authors investigated 8 T-helper cell clones (CD3+, CD4+, TCR.alpha./beta.) with specificity for Bet v I, the major birch pollen allergen, as proved by reactivity with purified natural as well as with recombinant allergen. The T cell clones were used to investigate common T cell **epitopes** of the Bet v I mol. with Cor a I, the major allergen of hazel pollen and Aln g I, the major allergen of alder pollen. All 8 T cell clones reacted with all three proteins with different intensity. Moreover, three T cell clones, which were known to react with immunodominant T cell **epitopes** on the Bet v I mol., were tested for reactivity with dodecapeptides synthesized according to the corresponding homologous regions of the Cor a I and Aln g I sequence. All the peptides induced strong T cell proliferation, indicating the existence of multiple cross-reacting **epitopes**. These findings will have an impact on the prodn. of vaccines for immunotherapy of tree pollen allergies.

ST Betula allergen T cell crossreactivity; **birch allergen**
T cell crossreactivity hazel; alder T cell crossreactivity **birch allergen**; tree pollen allergen T cell crossreactivity

IT Allergens
RL: BIOL (Biological study)
(Aln g I (Alnus glutinosa, I), T-cells to **birch allergen** crossreactivity with, in humans with type I allergy)

IT Pollen
(allergen I of, of birch, human allergic T-cells to, alder and hazel major allergen crossreactivity with)

IT Birch
(major allergen I of, human allergic T-cells to, alder and hazel major allergen crossreactivity by)

IT Alder
Hazel
(major allergen of, human allergic T-cells to birch major allergen crossreactivity with)

IT Allergens
RL: BIOL (Biological study)
(Bet v I (Betula verrucosa, I), T-cells of humans with type I allergy to, alder and hazel major allergen crossreactivity with)

IT Allergens
RL: BIOL (Biological study)
(Cor a I (Corylus avellana, I), T-cells to **birch**

allergen crossreactivity with, in humans with type I allergy)

IT Lymphocyte
(T-cell, to major allergen I of birch, of humans with type I allergy, alder and hazel major allergen crossreactivity by)

IT Allergy
(immediate hypersensitivity, T-cells to birch major allergen I in humans with, alder and hazel major allergen crossreactivity with)

IT 151901-22-3 151901-23-4 151901-24-5
RL: BIOL (Biological study)
(of major allergen I of alder, human T-cells to birch major allergen crossreactivity with)

IT 146819-50-3 151901-17-6 151901-18-7
RL: BIOL (Biological study)
(of major allergen I of birch, human allergic T-cells to, alder and hazel major allergen crossreactivity with)

IT 151901-19-8 151901-20-1 151901-21-2
RL: BIOL (Biological study)
(of major allergen I of hazel, human T-cells to birch major allergen crossreactivity with)

L5 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1993:167322 CAPLUS

DN 118:167322

TI Identification of multiple T cell **epitopes** on Bet v I, the major birch pollen allergen, using specific T cell clones and overlapping peptides

AL Ebner, C.; Szepefalusi, Z.; Ferreira, F.; Jilek, A.; Valenta, R.; Parronchi, P.; Maggi, E.; Romagnani, S.; Scheiner, O.; Kraft, D.

CS Inst. Gen. Exp. Pathol., Univ. Vienna, Vienna, A-1090, Austria

SO J. Immunol. (1993), 150(3), 1047-54

CODEN: JOIMA3; ISSN: 0022-1767

DT Journal

LA English

CC 15-9 (Immunochemistry)

AB Eleven T cell clones (TCC) with specificity for Bet v I were established from the peripheral blood of six birch pollen allergic donors. Bet v I

is

the major allergen of birch (*Betula verrucosa*) pollen and shows high homol. to the major allergens of pollens of other trees within the order Fagales (hazel, alder, hornbeam, oak, etc.), which represent important inhalant allergens in the northern hemisphere. The TCC were shown to react with purified natural, as well as with purified recombinant Bet v

I.

All clones showed the helper cell phenotype (CD3+CD4+) and expressed the TCR-.alpha../.beta.. The cytokine prodn. pattern in response to stimulation with allergen resulted in enhanced prodn. of interleukin (IL)-4 in 9 of 11 clones. The clones were used for T cell **epitope** mapping on the Bet v I mol. For this purpose, peptides with a length of 12 amino acids each and overlapping for 10 residues were synthesized following the amino acid sequence of Bet v I. These 75 peptides were

used

to stimulate Bet v I-specific T cell clones. The expts. revealed 7 distinct T cell **epitopes** on the Bet v I mol. The **epitopes** were scattered over the whole mol., 2 sequences were in agreement with an algorithm previously described for the prediction of T cell **epitopes**. In 3 cases, one could identify distinct TCC specificities within single individuals. Furthermore, for each donor, none of the peptides representing **epitopes** for TCC inhibited the

binding of IgE antibodies to Bet v I. These results suggest that T cells and IgE antibodies from the same individual recognize different structures

on the Bet v I allergen.

ST T cell **epitope birch allergen**; Betula allergen T cell **epitope**

IT Pollen

(of birch, Bet v I allergen of, T cell **epitopes** of)

IT Immunoglobulins

RL: BIOL (Biological study)

(E, binding **epitopes** for human, of Bet v I allergen)

IT Lymphocyte

(T-cell, helper cell, allergen Bet v I multiple **epitopes** for)

IT Lymphokines and Cytokines

RL: FORM (Formation, nonpreparative)

(interleukin 4, formation of, by T cells, Bet v I allergen induction of)

IT Allergens

RL: BIOL (Biological study)

(Bet v I (Betula verrucosa, I), multiple **epitopes** of, for T cell, IgE binding **epitopes** different from)

IT 146819-47-8 146819-48-9 146819-49-0 146819-50-3 146819-51-4
146819-52-5 146819-53-6 146819-54-7

RL: BIOL (Biological study)

(of Bet v I allergen, as T cell **epitope**)

L5 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1994:52558 CAPLUS

DN 120:52558

TI Studies on the biological activities of the amino terminal **epitope** 23-38 from the major birch pollen allergen Bet v I

AU Vik, H.; Steinsvaag, S. K.; Dybendal, T.; Florvaag, E.; Holen, E.; Elsayed, S.

CS Lab. Clin. Biochem., Univ. Bergen, Norway

SO Mol. Biol. Immunol. Allergens (1993), 223-5. Editor(s): Kraft, Dietrich; Sahon, Alec H. Publisher: CRC, Boca Raton, Fla.
CODEN: 59QMA6

DT Conference

LA English

CC 15-9 (Immunochemistry)

AB Peptide Bet v I 23-38 was demonstrated to bind IgE in vitro by RAST inhibition, in vivo by pos. skin prick tests in birch allergic individuals, mast cell degranulation in nasal mucosa, and by binding birch-specific IgE in Prausnitz Kustner inhibition tests. Bet v I 23-38 could be an IgE-binding haptenic **epitope**.

ST birch pollen allergen

IT **Birch**

(**allergen** of pollen of, biol. activities of N-terminal fragment of)

IT Pollen

(allergen of, of birch, biol. activities of N-terminal fragment of)

IT Allergens

RL: BIOL (Biological study)

(Bet v I (Betula verrucosa, I), biol. activities of N-terminal fragment of)

L5 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1992:505712 CAPLUS
 DN 117:105712
 TI Tree pollen allergens, cDNA encoding them, and their use in treatment and diagnosis of allergies
 IN Breiteneder, Heimo; Reikerstorfer, Arnold; Valenta, Rudolf; Hoffmann-Sommergruber, Karin; Breitenbach, Michael; Kraft, Dietrich; Rumpold, Helmut; Scheiner, Otto; Ebner, Christof; Ferreira, Fatima
 PA Biomay Biotechnik Produktions- und Handelsgesellschaft m.b.H., Austria
 SO PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C12N015-29
 ICS C07K013-00; C12N015-70; G01N033-53; C12Q001-02; A61K037-02
 CC 3-2 (Biochemical Genetics)
 Section cross-reference(s): 9, 15
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9202621	A2	19920220	WO 1991-EP1479	19910806
	WO 9202621	A3	19920514		
	W: AU, CA, FI, JP, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	AT 9001668	A	19951115	AT 1990-1668	19900808
	AT 401179	B	19960725		
	CA 2067144	AA	19920209	CA 1991-2067144	19910806
	AU 9183112	A1	19920302	AU 1991-83112	19910806
	AU 657917	B2	19950330		
	EP 495052	A1	19920722	EP 1991-914150	19910806
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05501656	T2	19930402	JP 1991-513157	19910806
	FI 9201524	A	19920407	FI 1992-1524	19920407
	NO 9201362	A	19920605	NO 1992-1362	19920407
	US 5693495	A	19971202	US 1992-847010	19920601
	AU 9513436	A1	19950629	AU 1995-13436	19950222

PRAI AT 1990-1668 19900808
 US 1991-683831 19910411
 WO 1991-EP1479 19910806

AB cDNAs encoding alder pollen allergen Aln g I, hazel pollen allergen Cor a I, and birch pollen allergen Bet v I are cloned and expressed in Escherichia coli. The allergens were recognized by IgE antibodies from sera of patients allergic to these pollens.

ST tree pollen allergen cDNA cloning; Aln g I allergen cDNA cloning; Cor a I allergen cDNA cloning; Bet v I allergen cDNA cloning; allergy treatment diagnosis pollen cDNA

IT Gene, plant

RL: BIOL (Biological study)

(cDNA, for pollen allergens Aln g I and Cor a I and Bet v I of alder and hazel and birch, cloning and expression in Escherichia coli of)

IT Molecular cloning

(of cDNAs for pollen allergens Aln g I and Cor a I and Bet v I of

alder

and hazel and birch, in Escherichia coli)

IT Deoxyribonucleic acid sequences

(of Aln g I and Cor a I and Bet v I pollen allergen cDNAs of alder and hazel and birch)

IT Protein sequences

(of Aln g I and Cor a I and Bet v I pollen allergen of alder and hazel

and birch)

IT Birch
(pollen allergen Bet v I of, cDNA for, cloning and expression in Escherichia coli of)

IT Alder
(pollen allergen Aln g I of, cDNA for, cloning and expression in Escherichia coli of)

IT Hazel
(pollen allergen Cor a I of, cDNA for, cloning and expression in Escherichia coli of)

IT Fagales
(pollen allergens of, cDNAs for, cloning and expression in Escherichia coli of)

IT Allergy
(treatment and diagnosis of, pollen allergens of hazel and birch and alder for)

IT Allergens
RL: BIOL (Biological study)
(Aln g I, cDNA for, of Aldus, cloning and expression in Escherichia coli of)

IT Allergens
RL: BIOL (Biological study)
(Cor a I, cDNA for, of Corylus, cloning and expression in Escherichia coli of)

IT Immunoglobulins
RL: ANT (Analyte); ANST (Analytical study)
(E, detection of, in allergy patients, pollen allergens of hazel and birch and alder for)

IT Allergens
RL: BIOL (Biological study)
(Bet v I (Betula verrucosa, I), cDNA for, of Betula, cloning and expression in Escherichia coli of)

IT 126161-14-6, Allergen Bet v I (Betula pendula clone pBV1 isoform protein moiety) 143066-16-4, Allergen Aln g I (alder) 143066-17-5, Allergen Cor a I (hazel isoform 1) 143066-18-6, Allergen Cor a I (hazel isoform 2) 143066-19-7, Allergen Cor a I (hazel isoform 3) 143066-20-0, Allergen Cor a I (hazel isoform 4)
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
(amino acid sequence of, complete, and expression in Escherichia coli of cDNA for)

IT 141101-72-6 141101-73-7 141101-74-8 141101-75-9 141101-76-0 141101-77-1
RL: BIOL (Biological study)
(**epitope** of Fagales pollen allergen)

IT 143068-37-5, Deoxyribonucleic acid (alder allergen Aln g I messenger RNA-complementary plus 3'-flanking region fragment) 143068-41-1, Deoxyribonucleic acid (**birch allergen** Bet v I messenger RNA-complementary plus 3'-flanking region fragment) 143068-64-8, Deoxyribonucleic acid (hazel allergen Cor a I isoform 3 messenger RNA-complementary minus terminator fragment) 143068-66-0, Deoxyribonucleic acid (hazel allergen Cor a I isoform 1 messenger RNA-complementary plus 3'-flanking region fragment) 143068-67-1, Deoxyribonucleic acid (hazel allergen Cor a I isoform 2 messenger RNA-complementary plus 3'-flanking region fragment) 143068-69-3, Deoxyribonucleic acid (hazel allergen Cor a I isoform 4 messenger RNA-complementary plus 3'-flanking region fragment)
RL: BIOL (Biological study)

(nucleotide sequence of and cloning in Escherichia coli of)
 IT 143068-36-4, Deoxyribonucleic acid (alder allergen Aln g I messenger
 RNA-complementary minus terminator fragment) 143068-40-0,
 Deoxyribonucleic acid (**birch allergen** Bet v I
 messenger RNA-complementary minus terminator fragment) 143068-62-6,
 Deoxyribonucleic acid (hazel allergen Cor a I isoform 1 messenger
 RNA-complementary minus terminator fragment) 143068-63-7,
 Deoxyribonucleic acid (hazel allergen Cor a I isoform 2 messenger
 RNA-complementary minus terminator fragment) 143068-65-9,
 Deoxyribonucleic acid (hazel allergen Cor a I isoform 4 messenger
 RNA-complementary minus terminator fragment) 143068-68-2,
 Deoxyribonucleic acid (hazel allergen Cor a I isoform 3 messenger
 RNA-complementary plus 3'-flanking region fragment)
 RL: PRP (Properties); BIOL (Biological study)
 (nucleotide sequence of, complete, and expression in Escherichia coli
 of)

L5 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1993:167338 CAPLUS

DN 118:167338

TI Homology of two cDNAs coding for birch pollen allergens with calmodulin:
 Protein-bound calcium affects the IgE-binding capacity
 AU Seiberler, Susanne; Scheiner, Otto; Kraft, Dietrich; Valenta, Rudolf
 CS Inst. Gen. Exp. Pathol., Univ. Vienna, Vienna, A-1090, Austria
 SO Int. Arch. Allergy Immunol. (1992), 99(2-4), 380-1
 CODEN: IAAIEG; ISSN: 1018-2438

DT Journal

LA English

CC 15-9 (Immunochemistry)

Section cross-reference(s): 3

AB Birch pollen is known to contain 2 well-defined allergens, Bet v I, a
 protein, which is a major allergen for 95% of the birch-pollen-allergic
 individuals, and birch profilin, identified as a novel type of plant pan
 allergen. Here, is reported the identification of 2 novel birch pollen
 allergens with a sequence homol. to calmodulin. Although both allergens
 are rare targets for patients' IgE (5-10%), they are of particular
 interest because both proteins require the native protein conformation

and

protein-bound Ca²⁺ for IgE binding. Thus, for the first time an IgE
epitope is described which is assembled by a polypeptide and a
 divalent cation, Ca²⁺.

ST birch pollen allergen **epitope** calcium complex; IgE binding birch
 pollen allergen calcium

IT Pollen

(allergen from birch, IgE **epitope** on, calcium-dependent,
 calmodulins in relation to)

IT **Birch**

(**allergen** from pollen of, IgE **epitope** on,
 calcium-dependent, calmodulins in relation to)

IT Calmodulins

RL: BIOL (Biological study)

(birch pollen allergens homologous to)

IT Allergens

RL: BIOL (Biological study)

(of birch pollen, IgE **epitope** on, calcium-dependent,
 calmodulins in relation to)

IT Protein sequences

(of calcium-dependent allergen, of birch pollen)

IT Immunoglobulins
RL: BIOL (Biological study)
(E, birch pollen allergen binding by, calcium-dependent **epitope**
in)

IT 7440-70-2, Calcium, biological studies
RL: BIOL (Biological study)
(IgE **epitope** on birch pollen allergen dependence on)

L5 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1991:183460 CAPLUS

DN 114:183460

TI Mapping of Bet v I **epitopes** by using murine monoclonal
antibodies

AU Marc-Series, I.; Boutin, Y.; Vrancken, E. R.; Hebert, J.

CS Unite Rech. Inflammation Immunol. Rhumatol., CHUL, Ste-Foy, PQ, G1V 4G2,
Can.

SO Int. Arch. Allergy Appl. Immunol. (1990), 92(3), 226-32

CODEN: IAAAAM; ISSN: 0020-5915

DT Journal

LA English

CC 15-2 (Immunochemistry)

AB The different determinants of birch pollen exts., as shown by SDS-PAGE
anal., range from 10 to 94 kDa. These determinants were then
electrotransferred on nitrocellulose strips and allowed to react with
human IgE Ab from sensitive patients in order to identify the allergenic
determinants. Several minor (43, 35, 28 and 21 kDa) and the major (17
kDa) allergenic determinants were identified. Murine monoclonal
antibodies (mAb) were then produced against the major allergenic
determinant (Bet v I) and their specificity confirmed by immunoblot. One
of them, mAb 3F10, was used to affinity-purify the Bet v I. The purity

of

this material was confirmed by SDS-PAGE anal. and its reactivity on
immunoblot against human IgE ensured its biol. activity. These mAb were
then sepd. into four families based on their pattern of reactivity with
Bet v I. Indeed, four different **epitopes** on the mol. were
identified. Binding inhibition studies using two of them (mAb 5F9 and
8F12) suggested that the **epitopes** of Bet v I recognized by these
mAb are not overlapping. However, the binding of 8H7 and 3F10 was
partially inhibited by 5F9 and the binding of 3F10, by 8F12. These data
suggest that those two latter **epitopes** are somewhat overlapping.
The mAb 5F9 could inhibit the binding of human IgE on the
affinity-purified Bet v I up to 40% and then shares a common idiotope

with

human specific IgE Ab of allergic patients.

ST Bet v I allergen **epitope**; birch pollen allergen **epitope**

IT Allergens

RL: BIOL (Biological study)

(Bet v I, **epitopes** of birch pollen, mapping of, monoclonal
antibodies for)

IT Pollen

(allergen Bet v I of birch, **epitopes** of, mapping of,
monoclonal antibodies for)

IT Birch

(allergen Bet v I of pollen of, **epitopes** of,
mapping of, monoclonal antibodies for)

L5 ANSWER 26 OF 26 MEDLINE

DUPLICATE 1

AN 91076141 MEDLINE

DN 91076141
 TI Cross-reactivity among the pollen proteins of birch and apple trees.
 AU Berrens L; van Dijk A G; Houben G F; Hagemans M L; Koers W J
 CS CBF Research Group, Madrid.
 SO ALLERGIE UND IMMUNOLOGIE, (1990) 36 (3) 147-56.
 Journal code: 3A4. ISSN: 0323-4398.
 CY GERMANY: Germany, Federal Republic of
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals
 EM 199103
 AB In the spring of 1986, the pollen were collected from apple trees in full blossom, and were investigated for their allergenicity. The patients selected for study were subjects with a combined inhalant allergy to birch pollen and an oral allergy to apple fruit. The apple pollen extract yielded about the same percentage of nondialysable substance as obtained from birch pollen. In contrast to the latter, UV-spectroscopy revealed no flavonoids adsorbed to the apple pollen proteins. Patients with a combined allergy to birch pollen and apple fruit showed positive skin reactions to both birch and apple pollen extract. Inhibition of IgE-binding in RAST to birch pollen was observed by apple pollen extract at a 1000-fold lower potency than the homologous **birch allergens**. Immunoblotting demonstrated IgG-antibodies in birch-allergic sera cross-reactive with apple pollen components. It is concluded that minor allergenic determinants cross-reactive with birch pollen **epitopes** occur not only in the fruit, but also in the pollen of the apple tree.
 CT Check Tags: Human
 Cross Reactions
 Fruit: IM, immunology
 *Hay Fever: IM, immunology
 Isoelectric Point
 *Pollen: IM, immunology
 Pollen: UL, ultrastructure
 Radioallergosorbent Test
 Skin Tests
 Spectrophotometry, Ultraviolet
 *Trees

=> s ipsen h

L6 0 IPSEN H

=> s spangfort md

L7 0 SPANGFORT MD

=> s larsen j

L8 7 LARSEN J

=> dup remove l8

PROCESSING COMPLETED FOR L8

L9 6 DUP REMOVE L8 (1 DUPLICATE REMOVED)

=> d 19 all 1-6

L9 ANSWER 1 OF 6 SCISEARCH COPYRIGHT 2000 ISI (R)
AN 2000:832780 SCISEARCH
GA The Genuine Article (R) Number: 369JV
TI Ab initio calculations for elucidation of the lanosterol 14
alpha-demethylation mechanism
AU CabreraVivas B M (Reprint); Melendez F J; MartinezAguilera L M R;
KubliGarfias C
CS PRIV 37 OTE 1602, COL EL MIRADOR, PUEBLA 72530, MEXICO (Reprint);
BENEMERITA UNIV AUTONOMA PUEBLA, FAC CIENCIAS QUIM, PUEBLA, MEXICO; UNIV
NACL AUTONOMA MEXICO, INST INVEST BIOMED, LAB QUIM HORMONAL, MEXICO CITY
04510, DF, MEXICO; INST MEXICANO PETR, MEXICO CITY 07730, DF, MEXICO
CYA MEXICO
SO JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM, (17 NOV 2000) Vol. 532, pp.
245-256.
Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM,
NETHERLANDS.
ISSN: 0166-1280.
DT Article; Journal
FS PHYS
LA English
REC Reference Count: 39
AB Ab initio calculations at the RHF/6-31G* level were performed with the
SPARTAN program in order to elucidate the best pathway through which
norlanosterol could be biosynthesized from lanosterol (demethylation).
Two
possible main pathways have been reported: the pathway via intermediate
carboxylic acid proposed by Olson and Akhtar [J.A. Olson, M. Lindberg, K.
Bloch, J. Biol. Chem. 226 (1957) 941-956; M. Akhtar, I.A. Watkinson, A.D.
Rahimtula, D.C. Wilton, K.A. Munday, Biochem. J. 111 (1969) 757-761], and
the pathway via intermediate formyloxy proposed by Alexander et al. [K.
Alexander, M. Akhtar, R.B. Boar, J.F. McGhie, D.H.R. Barton, J. Chem.
Sec.
Chem. Commun. (1972) 383-386; R.T. Fischer, J.M. Trzaskos, R.L. Magolda,
S.S. Koo, C.S. Brosz, B. Larsen, J. Biol. Chem. 266
(10) (1991) 6124-6132]. We conclude that the formyloxy pathway is more
feasible than the carboxylic acid pathway based on an analysis of
frontier
orbitals, hardness/softness and reactivity parameters. (C) 2000 Elsevier
Science B.V. All rights reserved.
CC CHEMISTRY, PHYSICAL
ST Author Keywords: 14 alpha-demethylation; HOMO; LUMO; hardness and
softness; exergonic and endergonic reactions
STP KeyWords Plus (R): 14-ALPHA-METHYL DEMETHYLASE; CHOLESTEROL-BIOSYNTHESIS;
OXIDATIVE DEMETHYLATION; C-32 DEMETHYLATION; YEAST MICROSOMES;
CYTOCHROME-P-450; INTERMEDIATE; ACCUMULATION
RE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)
AKHTAR M	1969	111	757	BIOCHEM J
AKHTAR M	1969	9	473	EUR J BIOCHEM
AKHTAR M	1968		1406	J CHEM SOC CHEM COMM
ALEXANDER K	1972		383	J CHEM SOC CHEM COMM

AOYAMA Y	1978	82	33	BIOCHEM BIOPH RES CO
AOYAMA Y	1978	85	28	BIOCHEM BIOPH RES CO
AOYAMA Y	1986	134	659	BIOCHEM BIOPH RES CO
AOYAMA Y	1962	259	16	J BIOL CHEM
AOYAMA Y	1989	264	2	J BIOL CHEM
CANONICA L	1968	90	3597	J AM CHEM SOC
CLAYTON R B	1956	218	319	J BIOL CHEM
DAWSON J H	1988	240	433	SCIENCE
EDWARDS J O	1962	84	16	J AM CHEM SOC
FIECCHI A	1972	180	147	P R LOND B
FIESER L F	1959	364	364	STEROIDS
FISCHER R T	1991	266	6124	J BIOL CHEM
FISCHER R T	1989	30	1621	J LIPID RES
FUKUI K	1982	218	747	SCIENCE
GAYLOR J L	1963	238	1649	J BIOL CHEM
GIBBONS G F	1979	183	309	BIOCHEM J
GOODMAN D S	1963	238	1287	J BIOL CHEM
GUENGERICH F P	1984	17	9	ACCOUNTS CHEM RES
JOHNSTON J D	1957	79	1145	J AM CHEM SOC
KLYNE W	1970		9	QUIMICA ESTEROIDES
KUBLIGARFIAS C	1996	388	35	J MOL STRUCT THEOCHE
LEHNINGER A L	1995		254	PRINCIPIOS BIOQUIMIC
LIU H I	1995	270	10544	J BIOL CHEM
OLSON J A	1957	226	941	J BIOL CHEM
PEARSON R G	1967	89	1827	J AM CHEM SOC
PEARSON R G	1966	151	172	SCIENCE
SCHROEPFER G J	1982	51	555	ANN REV BIOCH
SCHROEPFER G J	1961	236	1668	J BIOL CHEM
SCHROEPFER G J	1972	180	125	P ROY SOC LOND B BIO
SHAFIEE A	1986	27	1	J LIPID RES
TRZASKOS J M	1984	259	13402	J BIOL CHEM
TRZASKOS J M	1986	261	16937	J BIOL CHEM
WATKINSON I A	1971	121	131	BIOCHEM J
WHITE A	1968		80	PRINCIPLES BIOCH
WHITE R E	1980	49	315	ANN REV BIOCH

L9 ANSWER 2 OF 6 SCISEARCH COPYRIGHT 2000 ISI (R)
 AN 1998:624080 SCISEARCH
 GA The Genuine Article (R) Number: 109DW
 TI Internal generation of waves for time-dependent mild-slope equations
 AU Lee C (Reprint); Suh K D
 CS KOREA OCEAN RES & DEV INST, COASTAL & HARBOUR ENGN DIV, ANSAN POB 29,
 SEOUL 425600, SOUTH KOREA (Reprint); SEOUL NATL UNIV, DEPT CIVIL ENGN,
 SEOUL 151742, SOUTH KOREA
 CYA SOUTH KOREA
 SO COASTAL ENGINEERING, (JUL 1998) Vol. 34, No. 1-2, pp. 35-57.
 Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM,
 NETHERLANDS.
 ISSN: 0378-3839.
 DT Article; Journal
 FS ENGI
 LA English
 REC Reference Count: 21
 AB A technique for internal generation of waves is studied for two
 time-dependent mild-slope equation models developed by Copeland
 [Copeland,
 G.J.M., 1985. A practical alternative to the mild-slope wave equation.
 Coastal Eng., 9, pp. 125-149] and Radder and Dingemans [Radder, A.C.,

Dingemans, M.W., 1985. Canonical equations for almost periodic, weakly nonlinear gravity waves. Wave Motion, 7, pp. 473-485]. For the Radder and Dingemans' equations, desired energy of incident waves could not be obtained from the viewpoint of mass transport which has successfully been used for the Boussinesq equations and the Copeland equations by Larsen

and

Dancy [Larsen, J., Dancy, H., 1983. Open boundaries in short wave simulations-a new approach. Coastal Eng., 7, pp. 285-297] and Madsen and Larsen [Madsen, P.A., Larsen, J., 1987. An efficient finite-difference approach to the mild-slope equation. Coastal Eng., 11, pp. 329-351], respectively. However, for both of the Copeland's and Radder and Dingemans' models, desired energy of incident waves could be obtained from the viewpoint of energy transport. Using the viewpoint

of

energy transport in the Radder and Dingemans equations, which treat random

waves of narrow frequency band properly, we could successfully generate not only monochromatic waves but also directional random waves. (C) 1998 Elsevier Science B.V. All rights reserved.

CC ENGINEERING, CIVIL; ENGINEERING, MARINE

ST Author Keywords: time-dependent mild-slope equations; numerical wave generation; energy transport

STP KeyWords Plus (R): LINEAR DISPERSION CHARACTERISTICS; BOUSSINESQ EQUATIONS; FORM

RE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)
BERKHOFF J C W	1972		471	13TH P INT C COAST E
BOUIJ N	1981			811 DELFT U TECH DEP
COPELAND G J M	1985 9		125	COAST ENG
KIM T	1994		340	P 2J INT C COAST ENG
KIRBY J T	1984 89		745	J GEOPHYS RES OCEANS
KIRBY J T	1992		391	P 23 INT C COAST ENG
KOBUNE K	1986		80	P 5 INT OFFSH MECH A
KUBO Y	1992		419	P 20 INT C COAST ENG
LARSEN J	1983 7		285	COAST ENG
LEE C	1994			THESIS U DELAWARE
LEE C H	1994 6		389	J KOREAN SOC COASTAL
MADSEN P A	1987 11		329	COAST ENG
MADSEN P A	1991 15		371	COAST ENG
MADSEN P A	1992 18		183	COAST ENG
NISHIMURA H	1983		123	P 30 JAP C COAST ENG
NWOGU O	1993 119		618	J WATERW PORT C ASCE
OTNES R K	1978 1			APPLIED TIME SERIES
PEREGRINE D H	1967 27		815	J FLUID MECH
RADDER A C	1985 7		473	WAVE MOTION
SMITH R	1975 72		373	J FLUID MECH
YOON S B	1996 16		53	J KOREAN SOC CIVIL E

L9 ANSWER 3 OF 6 MEDLINE

DUPLICATE 1

AN 85018257 MEDLINE

DN 85018257

TI Mechanism of inhibition of herpesvirus growth by 2'-5'-linked trimer of 9-beta-D-xylofuranosyladenine.

AU Goswami B B; Gosselin G; Imbach J L; Sharma O K

NC CA 23536 (NCI)

SO VIROLOGY, (1984 Sep) 137 (2) 400-7.

Journal code: XEA. ISSN: 0042-6822.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

EM 198501

AB The 2'-5'-linked trimer of 9-beta-D-xylofuranosyladenine (XyloA)3 is an extremely potent inhibitor of growth of herpes simplex viruses 1 and 2. Evidence is presented that in spite of its increased stability in cell-free extracts (D.A. Eppstein, Y.V. Marsh, B.B. Schryver, M.A. Larsen, J.W. Barnett, J.P.H. Verheyden, and E.J. Prisbe, J. Biol. Chem. 257, 13390-13397, 1982), intact (XyloA)3 was not detected in Vero cells, but instead was rapidly degraded in the medium to monomeric 9-beta-D-xylofuranosyladenine (XyloA). The XyloA thus formed was rapidly taken up by cells, phosphorylated to its triphosphate, and produced inhibition of RNA synthesis. The observed inhibition of DNA synthesis (D.A. Eppstein, Y.V. Marsh, B.B. Schryver, M.A. Larsen, J.W. Barnett, J.P.H. Verheyden, and E.J. Prisbe, J. Biol. Chem. 257, 13390-13397, 1982) and herpesvirus growth by (XyloA)3 (D.A. Eppstein, J.W. Barnett, Y.V. Marsh, G. Gosselin, and J.L. Imbach, Nature (London) 302, 723, 724, 1983) is most likely the result of inhibition of RNA synthesis by its degradation product XyloA.

CT Check Tags: Animal; Comparative Study; Support, Non-U.S. Gov't; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.

Acyclovir: PD, pharmacology

*Adenosine: AA, analogs & derivatives

Adenosine: PD, pharmacology

*Antiviral Agents: PD, pharmacology

Cell Line

Cercopithecus aethiops

Kidney

*Simplexvirus: DE, drug effects

Simplexvirus: GD, growth & development

Simplexvirus: GE, genetics

Species Specificity

Transcription, Genetic: DE, drug effects

Vidarabine: PD, pharmacology

RN 4185-03-9 (9-xylosyladenine); 5536-17-4 (Vidarabine); 58-61-7 (Adenosine); 59277-89-3 (Acyclovir)

CN 0 ((2'-5')-9-xylofuranosyladenine trimer); 0 (Antiviral Agents)

L9 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2000 ACS

AN 1974:126869 CAPLUS

DN 80:126869

TI Exact finite-range DWBA [distorted-wave Born analysis] analyses of (12C,11B) and (12C,13C) reaction from lead-208

AU Low, K. S.; Tamura, T.

CS Cent. Nucl. Stud., Univ. Texas, Austin, Tex., USA

SO Phys. Lett. B (1974), 48(4), 285-9

CODEN: PYLBAJ

DT Journal

LA English

CC 75-1 (Nuclear Phenomena)

AB A rapid exact finite-range DWBA calcn. is discussed and applied to the anal. of (12C, 11B) and (12C, 13C) reactions on 208Pb. The calcd. angular

distributions were compared with expt. (Larsen, J. S., et al., 1972); rather good agreement was obtained. Good relative spectroscopic factors were extd. from 209Bi and 207Pb states the abs. spectroscopic factors were correct to within a factor of 2 at the worst, and much better in general.

ST carbon lead 208 reaction; boron 11 prodn carbon; carbon 13 prodn carbon; bismuth 209 level; lead 207 level

IT Nuclear energy level
(of bismuth-209 and lead-207, from carbon-12 bombardment of lead-208, calcn. of spectroscopic factors for)

IT 13966-28-4, reactions
RL: RCT (Reactant)
(bombardment of, by carbon-12, calcn. of angular distributions of boron-11 and carbon-13 from)

IT 14762-74-4P, preparation 14798-13-1P, preparation
RL: PREP (Preparation)
(from lead-208 by carbon-12 bombardment, angular distributions of, calcn. of)

IT 7440-69-9, properties
RL: PRP (Properties)
(nuclear energy levels of bismuth-209, from carbon-12 bombardment of lead-208, calcn. of spectroscopic factors for)

IT 14119-29-0, properties
RL: PRP (Properties)
(nuclear energy levels of, from carbon-12 bombardment of lead-208, calcn. of spectroscopic factors for)

L9 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2000 ACS
AN 1970:89610 CAPLUS
DN 72:89610
TI Protonation of 9-ethyl-10-methylanthracene. Absence of a large Baker-Nathan effect in alkylarenium-ion-formation
AU Brouwer, D. M.; Van Doorn, J. A.
CS Kon./Shell-Lab., Shell Res. N. V., Amsterdam, Neth.
SO Recl. Trav. Chim. Pays-Bas (1970), 89(1), 88-96
CODEN: RTCPA3
DT Journal
LA English
CC 22 (Physical Organic Chemistry)
GI For diagram(s), see printed CA Issue.
AB Protonation of 9-ethyl-10-methylanthracene in HF or CF₃CO₂H/H₂O.BF₃ affords a mixt. of the 9H⁺- (I) and 10H⁺-9-ethyl-10-methylanthracenium ions (II). These ions differ in free energy by only 0.9-1.0 kcal/mole. This small difference in stability between I and II, which is probably due to steric rather than electronic effects, shows that methyl and ethyl groups are approx. equally effective in stabilizing arenium ions. This result demonstrates, contrary to what was recently concluded (Arnett, E. M.; Larsen, J. W.; 1969) on the basis of calorimetric measurements of the heats of protonation of alkylbenzenes in FSO₃H-SbF₅, that there is no large Baker-Nathan effect in alkylarenium-ion formation. The PMR spectrum of I exhibits some remarkable features (notably an unusually strong shielding of the ethyl-CH₃ protons) that are assocd. with the particular conformation of the (>CH₂Et) group in this ion and related ones.

ST anthracenes protonation; protonation anthracenes; Baker Nathan effects arenium ions; arenium ions Baker Nathan effects

IT Conjugation
 (hyper-, protonation of ethylmethylantracene in relation to)
 IT Protonation
 (of ethylmethylantracene, hyperconjugation in relation to)
 IT 27746-05-0 27746-06-1
 RL: PRP (Properties)
 (nuclear magnetic resonance of)
 IT 19713-49-6
 RL: RCT (Reactant)
 (protonation of, hyperconjugation in relation to)

L9 ANSWER 6 OF 6 MEDLINE
 AN 58112777 MEDLINE
 DN 58112777
 TI [].

Jacob Kjaer-Larsen; 22/2 1921-9/5 1958.
 AU PETERSEN P B
 SO Ugeskr. laeger, (1958 May 22) 120 (21) 684-5.
 LA Danish
 FS OLDMEDLINE
 OS CLML5834-62430-424
 EM 195812
 NA **KJAER-LARSEN J A C O B**

=> s fagales allergen and IgE binding

L10 2 FAGALES ALLERGEN AND IGE BINDING

=> d l10 all 1-2

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2000 ACS
 AN 1999:614141 CAPLUS
 DN 131:241995
 TI Mutant recombinant allergens for use as allergy vaccines
 IN Ipsen, Hans Henrik; Spangfort, Michael Dho; Larsen, Jorgen Nedergaard
 PA Alk-Abello A/S, Den.
 SO PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C12N015-29
 ICS C12N015-12; C07K014-415; C07K014-435; A61K039-35; A61K039-36
 CC 15-9 (Immunochemistry)
 Section cross-reference(s): 3

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9947680	A1	19990923	WO 1999-DK136	19990316
	W:		AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,		

CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 9927147 A1 19991011 AU 1999-27147 19990316
 PRAI DK 1998-364 19980316
 WO 1999-DK136 19990316
 AB Novel recombinant allergens are disclosed. The allergens are non-naturally occurring mutants derived from naturally-occurring allergens. The overall .alpha.-carbon backbone tertiary structure is essentially preserved. Also disclosed are methods for prep. such recombinant allergens as well as uses thereof. The invention is based on the idea that the mechanism of successful allergy vaccination is not an alteration of the ongoing Th2-type immune response, but rather a parallel initiation of a new Th1-type immune response involving tertiary epitope recognition by B-cells and antibody formation. Addnl., dominant **IgE binding** epitopes are proposed. These epitopes are supposed to be constituted by tertiary structure dependent coherent surface areas large enough to accommodate antibody binding and conserved among isoallergens, variants, and/or homologous allergens from related species. Mutant forms of Bet v 1 and Ves v 5 allergens were produced. The Bet v 1 mutants displayed reduced **IgE binding** although the tertiary structure of the wild-type Bet v 1 allergen was retained. A "triple-patch mutant" of Bet v 1 was able to induce proliferation in T cell lines from 3 different birch pollen allergic patients with stimulation indexes similar to recombinant and naturally occurring Bet v 1.
 ST allergy vaccine allergen mutant B cell epitope **IgE binding**; Bet v 1 allergen recombinant mutant allergy vaccine; Ves v 5 allergen recombinant mutant allergy vaccine
 IT Epitopes
 (B cell, mutation of; mutant recombinant allergens for use as allergy vaccines)
 IT Allergens
 RL: BPN (Biosynthetic preparation); BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (Bet v I (Betula verrucosa, I); mutant recombinant allergens for use as
 as allergy vaccines)
 IT Immunoglobulins
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (E, binding of, redn. of; mutant recombinant allergens for use as allergy vaccines)
 IT Ant (Formicidae)
 (Formicoidae; mutant recombinant allergens for use as allergy vaccines)
 IT Dicotyledon (Magnoliopsida)
 (Oleales; mutant recombinant allergens for use as allergy vaccines)
 IT Monocotyledon (Liliopsida)
 (Poales; mutant recombinant allergens for use as allergy vaccines)
 IT Allergens
 RL: BPN (Biosynthetic preparation); BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (Ves v 5 (Vespula vulgaris, V); mutant recombinant allergens for use as
 as allergy vaccines)
 IT Animal
 Apidae
 Asterales

Blattaria
 Cat (Felis catus)
 Dermatophagoides
 Dog (Canis familiaris)
Fagales
 Horse (Equus caballus)
 Hymenoptera
 Pinales
 Pollen
 Urticales
 Venoms
 Wasp

(allergens; mutant recombinant allergens for use as allergy vaccines)
 IT Vaccines
 (allergy; mutant recombinant allergens for use as allergy vaccines)
 IT Tertiary structure
 (maintenance of; mutant recombinant allergens for use as allergy vaccines)
 IT Allergy inhibitors
 (mutant recombinant allergens for use as allergy vaccines)
 IT Allergens
 RL: BPN (Biosynthetic preparation); BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (mutant recombinant allergens for use as allergy vaccines)
 IT Protein sequences
 (of Bet v 1 and Ves v 5 mutants)
 IT 244065-79-0P 244065-81-4P 244065-82-5P 244065-83-6P 244065-84-7P
 244065-85-8P 244065-86-9P 244065-87-0P 244065-88-1P 244065-89-2P
 244065-90-5P
 RL: BPN (Biosynthetic preparation); BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (amino acid sequence; mutant recombinant allergens for use as allergy vaccines)
 IT 244179-41-7, PN: WO9947680 FIG: 3 unclaimed DNA 244179-50-8, PN: WO9947680 FIG: 3 unclaimed DNA 244179-51-9, PN: WO9947680 FIG: 3 unclaimed DNA 244179-52-0, PN: WO9947680 FIG: 3 unclaimed DNA 244179-54-2, PN: WO9947680 FIG: 3 unclaimed DNA 244179-56-4, PN: WO9947680 FIG: 3 unclaimed DNA 244179-57-5, PN: WO9947680 FIG: 3 unclaimed DNA 244179-58-6, PN: WO9947680 FIG: 3 unclaimed DNA 244179-59-7, PN: WO9947680 FIG: 3 unclaimed DNA 244179-60-0, PN: WO9947680 FIG: 3 unclaimed DNA 244179-61-1, PN: WO9947680 FIG: 3 unclaimed DNA 244179-62-2, PN: WO9947680 FIG: 3 unclaimed DNA 244179-64-4, PN: WO9947680 FIG: 13 unclaimed DNA 244179-67-7, PN: WO9947680 FIG: 13 unclaimed DNA 244179-68-8, PN: WO9947680 FIG: 13 unclaimed DNA
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; mutant recombinant allergens for use as allergy vaccines)
 RE.CNT 6
 RE
 (1) Ferreira, F; FASEB JOURNAL FOR EXPERIMENTAL BIOLOGY 1998, V12(2), P231 CAPLUS
 (2) Hoffman, D; JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 1993, V92(5), P707 MEDLINE

- (3) Smith, A; CLINICAL AND EXPERIMENTAL ALLERGY 1997, V27(5), P593 CAPLUS
- (4) Spangfort, M; INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 1997, V113(1-3), P243 CAPLUS
- (5) The Rockefeller University; WO 9733910 A 1997 CAPLUS
- (6) Wiedemann, P; JOURNAL OF BIOLOGICAL CHEMISTRY 1996, V271(47), P29915 CAPLUS

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS

AN 1993:232158 CAPLUS

DN 118:232158

TI Four recombinant isoforms of Cor a I, the major allergen of hazel pollen, show different **IgE-binding** properties

AU Breiteneder, Heimo; Ferreira, Fatima; Hoffmann-Sommergruber, Karin; Ebner,

Christof; Breitenbach, Michael; Rumpold, Helmut; Kraft, Dietrich; Scheiner, Otto

CS Inst. Gen. Exp. Pathol., Univ. Vienna, Vienna, A-1090, Austria

SO Eur. J. Biochem. (1993), 212(2), 355-62

CODEN: EJBCAI; ISSN: 0014-2956

DT Journal

LA English

CC 15-9 (Immunochemistry)

Section cross-reference(s): 3, 11

AB Previous studies showed that pollens from trees of the order Fagales (e.g.

birch, alder, hazel, and hornbeam) all contain 1 major allergen. These proteins are cross-reactive among these tree species, and .apprx.95% of tree-pollen-allergic patients display **IgE binding** to these allergens. Using the reported N-terminal amino acid sequence of

the

hazel pollen allergen Cor a I, it was possible to amplify Cor-.alpha.-I cDNA by use of PCR. Four clones with cDNA inserts were isolated. All 4 clones contained an open reading frame of 477 nucleotides (159 amino acids) but differed in length for their 3'-non-coding regions. Within

the

overlapping regions, the nucleotide sequence of the 3'-non-coding regions of the 4 clones were nearly identical. The open reading frames coded for different isoforms of the major hazel pollen allergen, Cor a I. The clones were designated Cor a I/5, 6, 11 and 16, resp. Comparison of the deduced amino acid sequences of these Cor a I isoforms revealed

identities

of 96-99%. The sequence identities between the Cor a I isoforms and Bet

v

I, the major birch pollen allergen, were 71-73% (80.5-83% similarity).

Comparing amino acid sequences of Cor a I isoforms with the published sequences of Aln g I, the major allergen from alder, and Car b I and isoforms, the major allergen from hornbeam, 75.5-76.7% identity (83.6-85% similarity) and 83.6-89.9% sequence identity (89.3-95% similarity),

resp.,

was found. The 4 Cor a I cDNAs were subcloned into plasmid pKK223-3 and expressed in Escherichia coli as non-fusion proteins; their capacity to bind serum IgE from tree-pollen-allergic patients was investigated. The

4

cloned isoforms showed an apparent mol. mass of 17 kDa in SDS/PAGE, identical to the natural, pollen-derived Cor a I. IgE antibodies from tree-pollen-allergic patients reacted with all 4 recombinant isoforms. However, marked differences were noted in the **IgE-binding** patterns of the distinct isoforms. Furthermore, Cor a

I/11 was the only isoform recognized by the anti-(Ber v I) monoclonal antibody, BIP 1. These results demonstrate that Cor a I isoforms display different antigenic and allergenic properties, very likely due to few but significant changes in their amino acid sequences. These findings have implications for the development of reagents for diagnosis and immunotherapy for type I allergies.

ST hazel pollen allergen isoform; Corylus major allergen I sequence

IT **Fagales**

(allergens of pollen of, human IgE to, hazel major allergen I isoforms reactivity for)

IT Protein sequences

(for allergen I isoforms of hazel)

IT Immunoglobulins

RL: BIOL (Biological study)

(E, to allergen I of hazel, of humans, isoform reactivity of)

IT Deoxyribonucleic acid sequences

(complementary, for allergen I isoforms of hazel)

IT Allergy

(immediate hypersensitivity, IgE to tree pollen of humans with, hazel major allergen I isoform reactivity of)

IT 143066-17-5, Allergen Cor a I (hazel isoform 1) 143066-18-6, Allergen Cor a I (hazel isoform 2) 143066-19-7, Allergen Cor a I (hazel isoform 3) 143066-20-0, Allergen Cor a I (hazel isoform 4)

RL: PRP (Properties)

(amino acid sequence of)

=> logout

LOGOUT IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	114.35	114.50
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-16.14	-16.14

STN INTERNATIONAL LOGOFF AT 14:06:42 ON 10 DEC 2000